{"content":"<li class=\"n-box-item date-title\" data-end=\"1573275599\" data-start=\"1573189200\" data-txt=\"Monday, December 23, 2019\">Friday, November  8, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3517388\" data-ts=\"1573257108\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTSI\" target=\"_blank\">FTSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517388-ftsiminus-4_6-on-holder-filing-to-offer-76_4m-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FTSI -4.6% on holder filing to offer 76.4M shares</a></h4><ul>   <li>FTS International (NYSE:<a href='https://seekingalpha.com/symbol/FTSI' title='FTS International, Inc.'>FTSI</a>) has <font color=\"red\">dropped 4.6%</font> after a holder filing to <a href=\"https://seekingalpha.com/filing/4694084\" target=\"_blank\">offer up to 76.4M shares</a>.</li>    <li>The company won't receive any proceeds from the sale of shares in the registration.</li>    <li>Selling shareholders include Maju Investments (holder of a 38.8% stake), CHK Energy Holdings (20.5%); Senja Capital (11.1%), and Hampton Asset Holding Ltd. (0.8%).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3517388\" data-linked=\"FTSI -4.6% on holder filing to offer 76.4M shares\" data-tweet=\"$FTSI - FTSI -4.6% on holder filing to offer 76.4M shares https://seekingalpha.com/news/3517388-ftsiminus-4_6-on-holder-filing-to-offer-76_4m-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3517388-ftsiminus-4_6-on-holder-filing-to-offer-76_4m-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517387\" data-ts=\"1573255392\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLSN\" target=\"_blank\">CLSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517387-celsionminus-4_9-amid-holder-filing-to-offer-4_5m-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Celsion -4.9% amid holder filing to offer 4.5M shares</a></h4><ul>   <li>Celsion (NASDAQ:<a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a>) is <font color=\"red\">4.9% lower</font> postmarket after shareholder Aspire Capital <a href=\"https://seekingalpha.com/filing/4693703\" target=\"_blank\">filed to offer up to 4.5M shares</a>.</li>    <li>The company won't receive proceeds from the share sale, but may receive up to $10M from selling shares to Aspire under a purchase agreement entered into Oct. 28.</li>    <li>Prior to the offering, Aspire Capital owned 400,000 shares, including 300,000 issued and sold to Aspire as part of a September 2018 purchase agreement.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3517387\" data-linked=\"Celsion -4.9% amid holder filing to offer 4.5M shares\" data-tweet=\"$CLSN - Celsion -4.9% amid holder filing to offer 4.5M shares https://seekingalpha.com/news/3517387-celsionminus-4_9-amid-holder-filing-to-offer-4_5m-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3517387-celsionminus-4_9-amid-holder-filing-to-offer-4_5m-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:23 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517383\" data-ts=\"1573253480\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SOLY\" target=\"_blank\">SOLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517383-soliton-holders-file-to-offer-1m-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Soliton holders file to offer 1M shares</a></h4><ul>   <li>Soliton (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLY' title='Soliton, Inc.'>SOLY</a>) is <font color=\"red\">down 1.5%</font> in light postmarket trading after a shareholder <a href=\"https://seekingalpha.com/filing/4693470\" target=\"_blank\">filing to offer shares</a>.</li>    <li>The filing registers just over 1M shares at a proposed maximum price of $10.24 each, setting up a $10.4M offering.</li>    <li>The company won't receive any proceeds.</li>    <li>Selling stockholders include Remeditex Ventures LLC, Vertical Holdings and ALS Investments LLC; after the offering, they would hold stakes of 53.5%, 1.8% and 2.5% respectively.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3517383\" data-linked=\"Soliton holders file to offer 1M shares\" data-tweet=\"$SOLY - Soliton holders file to offer 1M shares https://seekingalpha.com/news/3517383-soliton-holders-file-to-offer-1m-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3517383-soliton-holders-file-to-offer-1m-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517381\" data-ts=\"1573252709\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGRX\" target=\"_blank\">AGRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517381-agile-therapeuticsminus-10-on-filing-to-offer-20m-in-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Agile Therapeutics -10% on filing to offer $20M in shares</a></h4><ul>   <li>Agile Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AGRX' title='Agile Therapeutics, Inc.'>AGRX</a>) is <font color=\"red\">10.1% lower</font> postmarket after filing to offer $20M in shares.</li>    <li>That comes through a sales agreement with H.C. Wainwright.</li>    <li>Net proceeds of about $19.1M will be earmarked for general purposes, including seeking regulatory approval and a commercial plan for Twirla and advancing development of other potential product candidates.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3517381\" data-linked=\"Agile Therapeutics -10% on filing to offer $20M in shares\" data-tweet=\"$AGRX - Agile Therapeutics -10% on filing to offer $20M in shares https://seekingalpha.com/news/3517381-agile-therapeuticsminus-10-on-filing-to-offer-20m-in-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3517381-agile-therapeuticsminus-10-on-filing-to-offer-20m-in-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517377\" data-ts=\"1573252323\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517377-tupperware-brands-leads-after-hour-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tupperware Brands leads after hour losers</a></h4><ul><li><strong>Gainers: </strong>DRTT <font color=\"green\">+7.9%</font>. <a href='https://seekingalpha.com/symbol/EGO' title='Eldorado Gold Corporation'>EGO</a> <font color=\"green\">+3.2%</font>. <a href='https://seekingalpha.com/symbol/AU' title='AngloGold Ashanti Limited'>AU</a> <font color=\"green\">+1.9%</font>. <a href='https://seekingalpha.com/symbol/OBSV' title='ObsEva SA'>OBSV</a> <font color=\"green\">+1.7%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/TUP' title='Tupperware Brands Corporation'>TUP</a> <font color=\"red\">-9.4%</font>. <a href='https://seekingalpha.com/symbol/KRO' title='Kronos Worldwide, Inc.'>KRO</a> <font color=\"red\">-3.6%. </font><a href='https://seekingalpha.com/symbol/EAF' title='GrafTech International Ltd.'>EAF</a> <font color=\"red\">-3.4%</font>. <a href='https://seekingalpha.com/symbol/NBR' title='Nabors Industries Ltd.'>NBR</a> <font color=\"red\">-2.3%</font>. <a href='https://seekingalpha.com/symbol/TXMD' title='TherapeuticsMD, Inc.'>TXMD</a> <font color=\"red\">-1.8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517377\" data-linked=\"Tupperware Brands leads after hour losers\" data-tweet=\"$EGO $AU $OBSV - Tupperware Brands leads after hour losers https://seekingalpha.com/news/3517377-tupperware-brands-leads-after-hour-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3517377-tupperware-brands-leads-after-hour-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:32 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517360\" data-ts=\"1573249909\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PICO\" target=\"_blank\">PICO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517360-pico-holdings-reports-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PICO Holdings reports Q3 results</a></h4><ul><li>PICO Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/PICO' title='PICO Holdings, Inc.'>PICO</a>): Q3 GAAP EPS of $0.07.</li><li>Revenue of $4.25M</li><li>Shares <font color=\"green\">+1.33%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17693573-pico-holdings-inc-announces-results-third-quarter-2019\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3517360\" data-linked=\"PICO Holdings reports Q3 results\" data-tweet=\"$PICO - PICO Holdings reports Q3 results https://seekingalpha.com/news/3517360-pico-holdings-reports-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3517360-pico-holdings-reports-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:51 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517355\" data-ts=\"1573249461\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517355-slv-nugt-gdxj-jnug-and-dust-among-weekly-etf-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SLV, NUGT, GDXJ, JNUG and DUST among weekly ETF movers</a></h4><ul><li><strong>Gainers: </strong>Direxion Junior Gold Mine Bear 3X (NYSEARCA:<a href='https://seekingalpha.com/symbol/JDST' title='Direxion Daily Junior Gold Miners Index Bear 3x Shares ETF'>JDST</a>) <font color=\"green\">+24.9%</font>.</li><li>VS 3X Inv Silver (NASDAQ:<a href='https://seekingalpha.com/symbol/DSLV' title='VelocityShares 3x Inverse Silver ETN'>DSLV</a>) <font color=\"green\">+23.7%</font>.</li><li>Ipath US Treasury 10 Yr Bear ETN (BATS:<a href='https://seekingalpha.com/symbol/DTYS' title='iPath US Treasury 10-year Bear ETN'>DTYS</a>) <font color=\"green\">+21.2%</font>.</li><li>Gold Miners Bear 3X Direxion ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/DUST' title='Direxion Daily Gold Miners Index Bear 3x Shares ETF'>DUST</a>) <font color=\"green\">+20.6%</font>.</li><li>Natural Gas Bull 3X Direxion (NYSEARCA:<a href='https://seekingalpha.com/symbol/GASL' title='Direxion Daily Natural Gas Related Bull 3x Shares ETF'>GASL</a>) <font color=\"green\">+19.4%</font>.</li><li><strong>Losers: </strong>Direxion Junior Gold Mine Bull 3X (NYSEARCA:<a href='https://seekingalpha.com/symbol/JNUG' title='Direxion Daily Junior Gold Miners Index Bull 3x Shares ETF'>JNUG</a>) <font color=\"red\">-21.7%</font>.</li><li>VS 3X Silver (NASDAQ:<a href='https://seekingalpha.com/symbol/USLV' title='VelocityShares 3x Long Silver ETN'>USLV</a>) <font color=\"red\">-20.6%</font>.</li><li>Direxion Natural Gas Bear 3X (NYSEARCA:<a href='https://seekingalpha.com/symbol/GASX' title='Direxion Daily Natural Gas Related Bear 3X Shares ETF'>GASX</a>) <font color=\"red\">-19.7%</font>.</li><li>Gold Miners Bull 3X Direxion ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/NUGT' title='Direxion Daily Gold Miners Index Bull 3x Shares ETF'>NUGT</a>) <font color=\"red\">-18.2%</font>.</li><li>Ultra Silver Proshares (NYSEARCA:<a href='https://seekingalpha.com/symbol/AGQ' title='ProShares Ultra Silver ETF'>AGQ</a>) <font color=\"red\">-14.2%</font>.</li><li><strong>Top non-leveraged gainers: </strong>Natural Gas ETF FT (NYSEARCA:<a href='https://seekingalpha.com/symbol/FCG' title='First Trust Natural Gas ETF'>FCG</a>) <font color=\"green\">+6.8%</font>.</li><li>G-X Copper Miners ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/COPX' title='Global X Copper Miners ETF'>COPX</a>) <font color=\"green\">+5.5%</font>.</li><li>S&amp;P Smallcap Energy Invesco ETF (NASDAQ:<a href='https://seekingalpha.com/symbol/PSCE' title='Invesco Exchange-Traded Fund Trust II - Invesco S&P SmallCap Energy ETF'>PSCE</a>) <font color=\"green\">+5.0%</font>.</li><li>S&amp;P Oil &amp; Gas Expl &amp; Prod SPDR (NYSEARCA:<a href='https://seekingalpha.com/symbol/XOP' title='SPDR S&P Oil & Gas Exploration & Production ETF'>XOP</a>) <font color=\"green\">+4.7%</font>.</li><li>Ipatha.B Coffee Subindex TR ETN (NYSEARCA:<a href='https://seekingalpha.com/symbol/JO' title='iPath Series B Bloomberg Coffee Subindex Total Return ETN'>JO</a>) <font color=\"green\">+4.4%</font>.</li><li><strong>Top non-leveraged losers: </strong>Junior Gold Miners ETF Vaneck (NYSEARCA:<a href='https://seekingalpha.com/symbol/GDXJ' title='VanEck Vectors Junior Gold Miners ETF'>GDXJ</a>) <font color=\"red\">-7.6%</font>.</li><li>Global Gold Miners Ishares MSCI ETF (NASDAQ:<a href='https://seekingalpha.com/symbol/RING' title='iShares MSCI Global Gold Miners ETF'>RING</a>) <font color=\"red\">-7.4%</font>.</li><li>US Global Go Gold and Precious Metal Miners ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/GOAU' title='U.S. Global GO GOLD and Precious Metal Miners ETF'>GOAU</a>) <font color=\"red\">-7.2%</font>.</li><li>Silver Trust Ishares (NYSEARCA:<a href='https://seekingalpha.com/symbol/SLV' title='iShares Silver Trust ETF'>SLV</a>) <font color=\"red\">-7.0%</font>.</li><li>Physical Silver (NYSEARCA:<a href='https://seekingalpha.com/symbol/SIVR' title='Aberd Std Silvr Shs'>SIVR</a>) <font color=\"red\">-7.0%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517355\" data-linked=\"SLV, NUGT, GDXJ, JNUG and DUST among weekly ETF movers\" data-tweet=\"$JDST $DSLV $DTYS - SLV, NUGT, GDXJ, JNUG and DUST among weekly ETF movers https://seekingalpha.com/news/3517355-slv-nugt-gdxj-jnug-and-dust-among-weekly-etf-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3517355-slv-nugt-gdxj-jnug-and-dust-among-weekly-etf-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517332\" data-ts=\"1573247284\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OCUL\" target=\"_blank\">OCUL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517332-ocular-therapeutix-launches-cost-cutting-initiative-shares-up-3-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ocular Therapeutix launches cost-cutting initiative; shares up 3% after hours</a></h4><ul><li>Aimed at sharpening its focus on Dextenza (dexamethasone ophthalmic insert) 0.4 mg, Ocular Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/OCUL' title='Ocular Therapeutix, Inc.'>OCUL</a>) initiates a <a href=\"https://seekingalpha.com/pr/17693487-ocular-therapeutix-announces-strategic-update-operational-restructuring\" target=\"_blank\">restructuring initiative</a> that, it says, will save ~$11M in annual operating costs. It has not as yet specified the exact number of job cuts, but it will record a $0.7M charge this quarter for related expenses.</li><li>Shares up <font color=\"green\">3%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517332\" data-linked=\"Ocular Therapeutix launches cost-cutting initiative; shares up 3% after hours\" data-tweet=\"$OCUL - Ocular Therapeutix launches cost-cutting initiative; shares up 3% after hours https://seekingalpha.com/news/3517332-ocular-therapeutix-launches-cost-cutting-initiative-shares-up-3-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3517332-ocular-therapeutix-launches-cost-cutting-initiative-shares-up-3-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517324\" data-ts=\"1573246642\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517324-morgan-stanley-bullish-on-ericsson-neutral-on-nokia\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley bullish on Ericsson, Neutral on Nokia</a></h4><ul>   <li>Morgan Stanley has weighed in on two major Scandinavian telecom equipment makers, and comes out favoring Ericsson (<a href=\"http://seekingalpha.com/symbol/ERIC\" target=\"_blank\">ERIC</a> <font color=\"green\">+2.4%</font>).</li>    <li>The firm initiated coverage on Ericsson at Overweight, and assigned it a price target of 100 kronor; that implies 15% upside from today's closing price in Stockholm.</li>    <li>Meanwhile, it's started Nokia (NYSE:<a href='https://seekingalpha.com/symbol/NOK' title='Nokia Corporation'>NOK</a>) at Equal Weight. Its price target of \u20ac3.70 after a decline in Helsinki today implies about 14.6% upside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3517324\" data-linked=\"Morgan Stanley bullish on Ericsson, Neutral on Nokia\" data-tweet=\"$NOK $ERIC - Morgan Stanley bullish on Ericsson, Neutral on Nokia https://seekingalpha.com/news/3517324-morgan-stanley-bullish-on-ericsson-neutral-on-nokia?source=tweet\" data-url=\"https://seekingalpha.com/news/3517324-morgan-stanley-bullish-on-ericsson-neutral-on-nokia\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517321\" data-ts=\"1573245765\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZN\" target=\"_blank\">AZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517321-astrazenecas-farxiga-shows-cv-benefit-in-heart-failure-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AstraZeneca&#39;s Farxiga shows CV benefit in heart failure study</a></h4><ul><li>A <a href=\"https://seekingalpha.com/pr/17693396-new-data-phase-iii-dapa-hf-trial-showed-farxiga-reduced-worsening-heart-failure\" target=\"_blank\">subanalysis </a>of a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03036124?titles=dapa-hf&amp;spons=astrazeneca&amp;phase=2&amp;draw=2&amp;rank=1\" target=\"_blank\">DAPA-HF</a>, evaluating AstraZeneca's (<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca PLC'>AZN</a> <font color=\"green\">+1.1%</font>) Farxiga (dapagliflozin), on top of standard-of-care treatment, in heart failure patients with reduced ejection fraction (with or without type 2 diabetes) (T2D) showed a cardiovascular &#40;CV&#41; benefit. The data were presented at the American Society of Nephrology Kidney Week in Washington, DC.</li><li>Patients receiving the SGLT2 inhibitor experienced a 28% relative reduction in the risk of CV death or worsening heart failure event.</li><li>Farxiga was first approved in the U.S. in January 2014 for T2D. Last month, the FDA approved it to reduce the risk of hospitalization for heart failure in adults with T2D with established CV disease or multiple CV risk factors.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517321\" data-linked=\"AstraZeneca&#39;s Farxiga shows CV benefit in heart failure study\" data-tweet=\"$AZN - AstraZeneca&#39;s Farxiga shows CV benefit in heart failure study https://seekingalpha.com/news/3517321-astrazenecas-farxiga-shows-cv-benefit-in-heart-failure-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3517321-astrazenecas-farxiga-shows-cv-benefit-in-heart-failure-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:42 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517320\" data-ts=\"1573245198\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DXC\" target=\"_blank\">DXC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517320-dxc-acquires-virtual-clarity\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DXC acquires Virtual Clarity</a></h4><ul><li>DXC (<a href='https://seekingalpha.com/symbol/DXC' title='DXC Technology Company'>DXC</a> <font color='green'>+1%</font>) <a href=\"https://seekingalpha.com/pr/17693018-dxc-technology-acquires-virtual-clarity-accelerate-modernization-large-scale-enterprise\" target=\"_blank\">announces</a> acquiring the provider of IT-as-a-Service transformation advisory services for undisclosed terms.</li><li>Virtual Clarity helps solve large-scale IT modernization and application migration challenges.</li><li>DXC says the purchase builds on its acquisition of Luxoft earlier this year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517320\" data-linked=\"DXC acquires Virtual Clarity\" data-tweet=\"$DXC - DXC acquires Virtual Clarity https://seekingalpha.com/news/3517320-dxc-acquires-virtual-clarity?source=tweet\" data-url=\"https://seekingalpha.com/news/3517320-dxc-acquires-virtual-clarity\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517319\" data-ts=\"1573244671\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FGEN\" target=\"_blank\">FGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517319-fibrogen-up-16-safety-concerns-roxadustat-ebb\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FibroGen up 16% as safety concerns with roxadustat ebb</a></h4><ul><li>FibroGen (<a href='https://seekingalpha.com/symbol/FGEN' title='FibroGen, Inc.'>FGEN</a> <font color=\"green\">+15.6%</font>) rallies on a 6x surge in volume on the heels of safety data on lead drug roxadustat. <a href=\"https://seekingalpha.com/pr/17693404-fibrogen-announces-positive-phase-3-pooled-roxadustat-safety-efficacy-results-treatment\" target=\"_blank\">Pooled results</a> from six Phase 3 studies evaluating the candidate for the treatment of anemia in CKD patients showed a safety profile comparable to placebo, putting investors at ease over the issue.</li><li>The data were presented at the American Society of Nephrology Kidney Week in Washington, DC.</li><li>All six studies met the primary efficacy endpoint of mean hemoglobin change from baseline versus control.</li><li>Roxadustat is an orally administered small molecule inhibitor of <a href=\"https://en.wikipedia.org/wiki/Hypoxia-inducible_factors\" target=\"_blank\">hypoxia-inducible factor</a> &#40;HIF&#41; prolyl hydroxylase. HIF is a protein transcription factor that \"turns on\" the production of red blood cells (erythropoiesis). Its value proposition is the ability to maintain hemoglobin levels without affecting inflammation and potentially avoiding the need for ongoing intravenous iron repletion therapy as needed with epoetin alfa.</li><li>Related tickers: AstraZeneca (<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca PLC'>AZN</a> <font color=\"green\">+1.1%</font>), Astellas Pharma (<a href='https://seekingalpha.com/symbol/ALPMF' title='Astellas Pharma Inc.'>OTCPK:ALPMF</a> <font color=\"red\">-1.5%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3517319\" data-linked=\"FibroGen up 16% as safety concerns with roxadustat ebb\" data-tweet=\"$FGEN $AZN $ALPMF - FibroGen up 16% as safety concerns with roxadustat ebb https://seekingalpha.com/news/3517319-fibrogen-up-16-safety-concerns-roxadustat-ebb?source=tweet\" data-url=\"https://seekingalpha.com/news/3517319-fibrogen-up-16-safety-concerns-roxadustat-ebb\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517315\" data-ts=\"1573243448\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FGEN\" target=\"_blank\">FGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517315-fibrogen-gains-nearly-10-on-positive-test-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fibrogen gains nearly 10% on positive test results</a></h4><ul><li>The Roxadustat Phase III program pooled analyses showed positive efficacy and no increased cardiovascular risk in patients with anaemia from chronic kidney disease.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17693404-fibrogen-announces-positive-phase-3-pooled-roxadustat-safety-efficacy-results-treatment\" target=\"_blank\">Press Release</a></li><li><a href='https://seekingalpha.com/symbol/FGEN' title='FibroGen, Inc.'>FGEN</a> <font color=\"green\">+9.5%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3517315\" data-linked=\"Fibrogen gains nearly 10% on positive test results\" data-tweet=\"$FGEN - Fibrogen gains nearly 10% on positive test results https://seekingalpha.com/news/3517315-fibrogen-gains-nearly-10-on-positive-test-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3517315-fibrogen-gains-nearly-10-on-positive-test-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517312\" data-ts=\"1573242993\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517312-ui-tdc-mitk-and-arlo-among-tech-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UI, TDC, MITK and ARLO among tech movers</a></h4><ul><li><strong>Gainers: </strong>Ubiquiti (NYSE:<a href='https://seekingalpha.com/symbol/UI' title='Ubiquiti Inc.'>UI</a>) <font color=\"green\">+35%</font>.</li><li>TrueCar (NASDAQ:<a href='https://seekingalpha.com/symbol/TRUE' title='TrueCar, Inc.'>TRUE</a>) <font color=\"green\">+32%</font>.</li><li>Leaf Group (NYSE:<a href='https://seekingalpha.com/symbol/LEAF' title='Leaf Group Ltd.'>LEAF</a>) <font color=\"green\">+29%</font>.</li><li>QuinStreet (NASDAQ:<a href='https://seekingalpha.com/symbol/QNST' title='QuinStreet, Inc.'>QNST</a>) <font color=\"green\">+20%</font>.</li><li>Eventbrite (NYSE:<a href='https://seekingalpha.com/symbol/EB' title='Eventbrite, Inc.'>EB</a>) <font color=\"green\">+19%</font>.</li> <li><strong>Losers: </strong>Altair Engineering (NASDAQ:<a href='https://seekingalpha.com/symbol/ALTR' title='Altair Engineering Inc.'>ALTR</a>) <font color=\"red\">-21%</font>.</li><li>Teradata Corporation (NYSE:<a href='https://seekingalpha.com/symbol/TDC' title='Teradata Corporation'>TDC</a>) <font color=\"red\">-18%</font>.</li><li>Arlo Technologies (NYSE:<a href='https://seekingalpha.com/symbol/ARLO' title='Arlo Technologies, Inc.'>ARLO</a>) <font color=\"red\">-16%</font>.</li><li>Cambium Networks Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/CMBM' title='Cambium Networks Corporation'>CMBM</a>) <font color=\"red\">-16%</font>.</li><li>Mitek Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/MITK' title='Mitek Systems, Inc.'>MITK</a>) <font color=\"red\">-16%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3517312\" data-linked=\"UI, TDC, MITK and ARLO among tech movers\" data-tweet=\"$UI $TRUE $LEAF - UI, TDC, MITK and ARLO among tech movers https://seekingalpha.com/news/3517312-ui-tdc-mitk-and-arlo-among-tech-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3517312-ui-tdc-mitk-and-arlo-among-tech-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517393\" data-ts=\"1573241286\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZEUS\" target=\"_blank\">ZEUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517393-olympic-steel-sees-continued-double-digit-drop-in-steel-shipments\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Olympic Steel sees continued double-digit drop in steel shipments</a></h4><ul><li>Olympic Steel (<a href='https://seekingalpha.com/symbol/ZEUS' title='Olympic Steel, Inc.'>ZEUS</a> <font color='red'>-9.3%</font>) tumbles nearly 10% after narrowly missing <a href=\"https://seekingalpha.com/news/3517069-olympic-steel-eps-misses-0_01-misses-revenue\" target=\"_blank\">Q3 earnings</a> expectations and forecasting lower Q4 shipments than in the year-ago period.</li><li>ZEUS says it expects Q4 shipments will fall 11%-12% Y/Y to 229K-231K st from 259K st shipped in the prior-year quarter, after Q3 shipments slipped 12% Y/Y to 249K st.</li><li><a href=\"https://www.argusmedia.com/en/news/2012193-olympic-steel-expects-steel-shipments-down-in-4q\" target=\"_blank\">ZEUS says weak demand</a> in October will outweigh a recent pickup in  the market as steel mills in the U.S. make a push to increase hot-rolled  coil prices by $80/st.</li><li>The company's YTD steel shipments are down 11% Y/Y to 789K st, while specialty metal product shipments are 11% higher to  111K st.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517393\" data-linked=\"Olympic Steel sees continued double-digit drop in steel shipments\" data-tweet=\"$ZEUS - Olympic Steel sees continued double-digit drop in steel shipments https://seekingalpha.com/news/3517393-olympic-steel-sees-continued-double-digit-drop-in-steel-shipments?source=tweet\" data-url=\"https://seekingalpha.com/news/3517393-olympic-steel-sees-continued-double-digit-drop-in-steel-shipments\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:28 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517305\" data-ts=\"1573240685\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDR\" target=\"_blank\">MDR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517305-mcdermott-plunges-after-hq-construction-reportedly-halted\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">McDermott plunges after HQ construction reportedly halted</a></h4><ul><li>McDermott (<a href='https://seekingalpha.com/symbol/MDR' title='McDermott International, Inc.'>MDR</a> <font color='red'>-26.4%</font>) shares dive to new lows in the wake of a report that work on the company's Houston headquarters building has been stopped after MDR allegedly <a href=\"https://www.bizjournals.com/houston/news/2019/11/07/construction-on-mcdermotts-hq-comes-to-a-halt.html\" target=\"_blank\">fell behind on payments</a> to its general contractor.</li><li>MDR allegedly was $14.2M behind on its payments for work performed on the building as of Oct. 30, according to a lien filed by the builder, which told its subcontractors to stop work at the site due to the non-payment.</li><li>MDR is working with the contractor to finalize the remaining schedule for the construction and buildout of the space, a company spokesperson says.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517305\" data-linked=\"McDermott plunges after HQ construction reportedly halted\" data-tweet=\"$MDR - McDermott plunges after HQ construction reportedly halted https://seekingalpha.com/news/3517305-mcdermott-plunges-after-hq-construction-reportedly-halted?source=tweet\" data-url=\"https://seekingalpha.com/news/3517305-mcdermott-plunges-after-hq-construction-reportedly-halted\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>199&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517304\" data-ts=\"1573239755\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FGEN\" target=\"_blank\">FGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517304-fibrogen-shares-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FibroGen shares halted pending news</a></h4><ul><li>Nasdaq has suspended trading in FibroGen (<a href='https://seekingalpha.com/symbol/FGEN' title='FibroGen, Inc.'>FGEN</a> <font color='red'>-9.2%</font>) pending the release of news, in this case, roxadustat safety data at the American Society of Nephrology Kidney Week in Washington, DC.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517304\" data-linked=\"FibroGen shares halted pending news\" data-tweet=\"$FGEN - FibroGen shares halted pending news https://seekingalpha.com/news/3517304-fibrogen-shares-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3517304-fibrogen-shares-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517300\" data-ts=\"1573239585\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517300-montage-resources-and-centrus-energy-among-energy-materials-gainers-unit-and-mcdermott-among\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Montage Resources and Centrus Energy among Energy/Materials gainers; Unit and McDermott among losers</a></h4><ul><li><b>Gainers: </b>Montage Resources (NYSE:<a href='https://seekingalpha.com/symbol/MR' title='Montage Resources Corporation'>MR</a>) <font color=\"green\">+17%</font>. Centrus Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/LEU' title='Centrus Energy Corp.'>LEU</a>) <font color=\"green\">+17%</font>. Rayonier Advanced Materials (NYSE:<a href='https://seekingalpha.com/symbol/RYAM' title='Rayonier Advanced Materials Inc.'>RYAM</a>) <font color=\"green\">+12%</font>. Brigham Minerals (NYSE:<a href='https://seekingalpha.com/symbol/MNRL' title='Brigham Minerals, Inc.'>MNRL</a>) <font color=\"green\">+7%</font>. Kronos Worldwide (NYSE:<a href='https://seekingalpha.com/symbol/KRO' title='Kronos Worldwide, Inc.'>KRO</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers: </b>Unit (NYSE:<a href='https://seekingalpha.com/symbol/UNT' title='Unit Corporation'>UNT</a>) <font color=\"red\">-49%</font>. McDermott (NYSE:<a href='https://seekingalpha.com/symbol/MDR' title='McDermott International, Inc.'>MDR</a>) <font color=\"red\">-26%</font>. Mammoth Energy Services (NASDAQ:<a href='https://seekingalpha.com/symbol/TUSK' title='Mammoth Energy Services, Inc.'>TUSK</a>) <font color=\"red\">-17%</font>. Olympic Steel (NASDAQ:<a href='https://seekingalpha.com/symbol/ZEUS' title='Olympic Steel, Inc.'>ZEUS</a>) <font color=\"red\">-11%</font>. Exterran (NYSE:<a href='https://seekingalpha.com/symbol/EXTN' title='Exterran Corporation'>EXTN</a>) <font color=\"red\">-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517300\" data-linked=\"Montage Resources and Centrus Energy among Energy/Materials gainers; Unit and McDermott among losers\" data-tweet=\"$MR $LEU $RYAM - Montage Resources and Centrus Energy among Energy/Materials gainers; Unit and McDermott among losers https://seekingalpha.com/news/3517300-montage-resources-and-centrus-energy-among-energy-materials-gainers-unit-and-mcdermott-among?source=tweet\" data-url=\"https://seekingalpha.com/news/3517300-montage-resources-and-centrus-energy-among-energy-materials-gainers-unit-and-mcdermott-among\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517299\" data-ts=\"1573239455\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENB\" target=\"_blank\">ENB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517299-enbridge-to-file-again-for-mainline-auction-after-regulatory-halt\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Enbridge to file again for Mainline auction after regulatory halt</a></h4><ul><li>Enbridge (<a href='https://seekingalpha.com/symbol/ENB' title='Enbridge Inc.'>ENB</a> <font color=\"green\">+2.1%</font>) says it <a href=\"https://www.reuters.com/article/us-enbridge-inc-results/enbridge-to-file-for-pipeline-overhaul-after-regulatory-halt-idUSKBN1XI1G9\" target=\"_blank\">will seek approval</a> from the Canada Energy Regulator to auction off rights to ship crude on its Mainline system, more than a month after the CER <a href=\"https://seekingalpha.com/news/3502734-enbridge-slides-regulators-mainline-ruling\" target=\"_blank\">stopped the company's earlier attempt</a> to contract space on the pipeline to shippers.</li><li>ENB, which also reported <a href=\"https://seekingalpha.com/news/3517152-enbridge-tops-q3-earnings-view-sees-full-year-dcf-guidance-midpoint\" target=\"_blank\">better than expected Q3 earnings</a>, said during its earnings conference call that it expects to place the Canadian portion of the Line 3 replacement into service on Dec.1 after delays.</li><li>Line 3 is part of ENB's Mainline network that transports western Canadian oil to refineries in the midwestern U.S., and the replacement project would double capacity to 760K bbl/day.</li><li>ENB also said it expects several of its growth projects to be operational in 2019, including the $700M Gray Oak pipeline, which is the biggest of three new pipelines connecting the Permian Basin to the Texas Gulf Coast.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517299\" data-linked=\"Enbridge to file again for Mainline auction after regulatory halt\" data-tweet=\"$ENB - Enbridge to file again for Mainline auction after regulatory halt https://seekingalpha.com/news/3517299-enbridge-to-file-again-for-mainline-auction-after-regulatory-halt?source=tweet\" data-url=\"https://seekingalpha.com/news/3517299-enbridge-to-file-again-for-mainline-auction-after-regulatory-halt\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517296\" data-ts=\"1573238380\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OXY\" target=\"_blank\">OXY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517296-icahn-to-launch-proxy-fight-occidental-petroleum-slams-anadarko-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Icahn to launch proxy fight at Occidental Petroleum, slams Anadarko deal</a></h4><ul><li>Occidental Petroleum (<a href='https://seekingalpha.com/symbol/OXY' title='Occidental Petroleum Corporation'>OXY</a> <font color='green'>+2.2%</font>) spikes higher after activist investor Carl Icahn <a href=\"https://www.thestreet.com/investing/stocks/occidental-petroleum-jumps-after-carl-icahn-trims-stake-vows-2020-proxy-fight-15160268\" target=\"_blank\">cut his stake</a> in the company by nearly a third while vowing to launch a proxy fight against the board next year.</li><li>In a <a href=\"https://www.sec.gov/Archives/edgar/data/797468/000092846419000091/oxydfan14a110819.htm\" target=\"_blank\">letter to shareholders</a>, Icahn reaffirms his fierce opposition to OXY's $38B deal for Anadarko Petroleum, calling it \"one of the worst I've ever seen.\"</li><li>\"The Oxy/Anadarko merger made no sense for stockholders, but perhaps it made sense for Vicki Hollub... and certain board members who, we believe, were concerned that OXY would be a takeover target, and therefore grossly overpaid to acquire Anadarko in order to protect themselves and their jobs,\" Icahn wrote.</li><li>\"Although OXY has dropped 42% since April, oil has only dropped 12%,\" Icahn said. \"We believe this is because Wall Street has completely lost faith in  Hollub and her board and has concluded, in my view, that Hollub and her board will put their interests far above the best interests of OXY's  stockholders.\"</li><li>Icahn says he has sold 10M shares in OXY and now holds 23M shares, valued at ~$900M; he had owned a $1.6B stake as of May 30.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517296\" data-linked=\"Icahn to launch proxy fight at Occidental Petroleum, slams Anadarko deal\" data-tweet=\"$OXY - Icahn to launch proxy fight at Occidental Petroleum, slams Anadarko deal https://seekingalpha.com/news/3517296-icahn-to-launch-proxy-fight-occidental-petroleum-slams-anadarko-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3517296-icahn-to-launch-proxy-fight-occidental-petroleum-slams-anadarko-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>91&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517295\" data-ts=\"1573237543\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XLRN\" target=\"_blank\">XLRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517295-acceleron-pharma-up-7-on-fda-nod-for-luspatercept\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acceleron Pharma up 7% on FDA nod for luspatercept</a></h4><ul><li>Acceleron Pharma (<a href='https://seekingalpha.com/symbol/XLRN' title='Acceleron Pharma Inc.'>XLRN</a> <font color=\"green\">+7%</font>) and collaboration partner Celgene (<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a> <font color=\"green\">+0.4%</font>) <a href=\"https://seekingalpha.com/pr/17693328-fda-approves-reblozyl-luspatercept-aamt-treatment-anemia-adults-beta-thalassemia-require\" target=\"_blank\">announce</a> FDA approval of Reblozyl (luspatercept-aamt) for the treatment of anemia in adult beta thalassemia patients who require regular red blood cell transfusions.</li><li>The companies will co-promote the product in the U.S.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517295\" data-linked=\"Acceleron Pharma up 7% on FDA nod for luspatercept\" data-tweet=\"$XLRN $CELG - Acceleron Pharma up 7% on FDA nod for luspatercept https://seekingalpha.com/news/3517295-acceleron-pharma-up-7-on-fda-nod-for-luspatercept?source=tweet\" data-url=\"https://seekingalpha.com/news/3517295-acceleron-pharma-up-7-on-fda-nod-for-luspatercept\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517294\" data-ts=\"1573237505\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517294-axon-enterprise-and-manitowoc-among-industrial-gainers-u-s-concrete-and-dixie-group-among\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Axon Enterprise and Manitowoc among Industrial gainers; U.S. Concrete and Dixie Group among losers</a></h4><ul><li><b>Gainers: </b>Axon Enterprise (NASDAQ:<a href='https://seekingalpha.com/symbol/AAXN' title='Axon Enterprise, Inc.'>AAXN</a>) <font color=\"green\">+24%</font>. Manitowoc (NYSE:<a href='https://seekingalpha.com/symbol/MTW' title='The Manitowoc Company, Inc.'>MTW</a>) <font color=\"green\">+18%</font>. NN (NASDAQ:<a href='https://seekingalpha.com/symbol/NNBR' title='NN, Inc.'>NNBR</a>) <font color=\"green\">+12%</font>. Terex (NYSE:<a href='https://seekingalpha.com/symbol/TEX' title='Terex Corporation'>TEX</a>) <font color=\"green\">+6%</font>. Triumph Group (NYSE:<a href='https://seekingalpha.com/symbol/TGI' title='Triumph Group, Inc.'>TGI</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>U.S. Concrete (NASDAQ:<a href='https://seekingalpha.com/symbol/USCR' title='U.S. Concrete, Inc.'>USCR</a>) <font color=\"red\">-21%</font>. Dixie Group (NASDAQ:<a href='https://seekingalpha.com/symbol/DXYN' title='The Dixie Group, Inc.'>DXYN</a>) <font color=\"red\">-10%</font>. Titan International (NYSE:<a href='https://seekingalpha.com/symbol/TWI' title='Titan International, Inc.'>TWI</a>) <font color=\"red\">-7%</font>. Ideal Power (NASDAQ:<a href='https://seekingalpha.com/symbol/IPWR' title='Ideal Power Inc.'>IPWR</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517294\" data-linked=\"Axon Enterprise and Manitowoc among Industrial gainers; U.S. Concrete and Dixie Group among losers\" data-tweet=\"$AAXN $MTW $NNBR - Axon Enterprise and Manitowoc among Industrial gainers; U.S. Concrete and Dixie Group among losers https://seekingalpha.com/news/3517294-axon-enterprise-and-manitowoc-among-industrial-gainers-u-s-concrete-and-dixie-group-among?source=tweet\" data-url=\"https://seekingalpha.com/news/3517294-axon-enterprise-and-manitowoc-among-industrial-gainers-u-s-concrete-and-dixie-group-among\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:25 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517293\" data-ts=\"1573237256\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IIVI\" target=\"_blank\">IIVI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517293-raymond-james-starts-ii-vi-outperform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Raymond James starts II-VI at Outperform</a></h4><ul>   <li>Raymond James has initiated coverage of II-VI (<a href=\"http://seekingalpha.com/symbol/IIVI\" target=\"_blank\">IIVI</a> <font color=\"red\">-2.7%</font>) at Outperform ahead of fiscal Q1 earnings.</li>    <li>The firm has a price target of $44, now implying 24% upside from a lower price today.</li>    <li>Sell-side analysts are <a href=\"https://seekingalpha.com/symbol/IIVI/ratings/sell-side-ratings\" target=\"_blank\">Bullish overall</a> and <a href=\"https://seekingalpha.com/symbol/IIVI/ratings/author-ratings\" target=\"_blank\">Seeking Alpha authors are Neutral</a>; the stock has a <a href=\"https://seekingalpha.com/symbol/IIVI/ratings/quant-ratings\" target=\"_blank\">Quant Rating of Neutral</a>.</li>    <li>II-VI will <a href=\"https://seekingalpha.com/symbol/IIVI/earnings\" target=\"_blank\">report earnings</a> before the market open on Tuesday; It's set a conference call for that day at 9 a.m. ET.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3517293\" data-linked=\"Raymond James starts II-VI at Outperform\" data-tweet=\"$IIVI - Raymond James starts II-VI at Outperform https://seekingalpha.com/news/3517293-raymond-james-starts-ii-vi-outperform?source=tweet\" data-url=\"https://seekingalpha.com/news/3517293-raymond-james-starts-ii-vi-outperform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:20 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517291\" data-ts=\"1573236940\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517291-farmer-bros-and-pyxus-international-among-consumer-gainers-modine-manufacturing-and-energous\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Farmer Bros. and Pyxus International among Consumer gainers; Modine Manufacturing and Energous among losers</a></h4><ul><li><b>Gainers: </b>Farmer Bros. (NASDAQ:<a href='https://seekingalpha.com/symbol/FARM' title='Farmer Bros. Co.'>FARM</a>) <font color=\"green\">+21%</font>. Pyxus International (NYSE:<a href='https://seekingalpha.com/symbol/PYX' title='Pyxus International, Inc.'>PYX</a>) <font color=\"green\">+13%</font>. SunOpta (NASDAQ:<a href='https://seekingalpha.com/symbol/STKL' title='SunOpta Inc.'>STKL</a>) <font color=\"green\">+10%</font>. GoPro (NASDAQ:<a href='https://seekingalpha.com/symbol/GPRO' title='GoPro, Inc.'>GPRO</a>) <font color=\"green\">+9%</font>. Village Farms International (NASDAQ:<a href='https://seekingalpha.com/symbol/VFF' title='Village Farms International, Inc.'>VFF</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers: </b>Modine Manufacturing (NYSE:<a href='https://seekingalpha.com/symbol/MOD' title='Modine Manufacturing Company'>MOD</a>) <font color=\"red\">-39%</font>. Energous (NASDAQ:<a href='https://seekingalpha.com/symbol/WATT' title='Energous Corporation'>WATT</a>) <font color=\"red\">-21%</font>. Nautilus (NYSE:<a href='https://seekingalpha.com/symbol/NLS' title='Nautilus, Inc.'>NLS</a>) <font color=\"red\">-12%</font>. Revlon (NYSE:<a href='https://seekingalpha.com/symbol/REV' title='Revlon, Inc.'>REV</a>) <font color=\"red\">-8%</font>. Eastman Kodak (NYSE:<a href='https://seekingalpha.com/symbol/KODK' title='Eastman Kodak Company'>KODK</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517291\" data-linked=\"Farmer Bros. and Pyxus International among Consumer gainers; Modine Manufacturing and Energous among losers\" data-tweet=\"$FARM $PYX $STKL - Farmer Bros. and Pyxus International among Consumer gainers; Modine Manufacturing and Energous among losers https://seekingalpha.com/news/3517291-farmer-bros-and-pyxus-international-among-consumer-gainers-modine-manufacturing-and-energous?source=tweet\" data-url=\"https://seekingalpha.com/news/3517291-farmer-bros-and-pyxus-international-among-consumer-gainers-modine-manufacturing-and-energous\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517287\" data-ts=\"1573236256\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CGC\" target=\"_blank\">CGC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517287-pot-stocks-rally-bargain-hunters-move-in\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pot stocks rally as bargain hunters move in</a></h4><ul><li>Bargain hunters are moving into cannabis stocks today on no apparent news. Yesterday, Canopy Growth (<a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a> <font color=\"green\">+9.3%</font>) announced a <a href=\"https://seekingalpha.com/news/3516428-canopy-growth-launch-cannabis-company-rapper-drake-shares-2-percent\" target=\"_blank\">venture </a>with rapper Drake.</li><li>Selected tickers: Horizons Marijuana Life Sciences Index ETF (<a href='https://seekingalpha.com/symbol/HMLSF' title='Horizons Marijuana Life Sciences Index ETF'>HMLSF</a> <font color=\"green\">+5.2%</font>), Tilray (<a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a> <font color=\"green\">+4.9%</font>), Aurora Cannabis (<a href='https://seekingalpha.com/symbol/ACB' title='Aurora Cannabis Inc.'>ACB</a> <font color=\"green\">+3.1%</font>), Cronos Group (<a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group Inc.'>CRON</a> <font color=\"green\">+3.5%</font>), Aphria (<a href='https://seekingalpha.com/symbol/APHA' title='Aphria Inc.'>APHA</a> <font color=\"green\">+3.5%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3517287\" data-linked=\"Pot stocks rally as bargain hunters move in\" data-tweet=\"$CGC $TLRY $ACB - Pot stocks rally as bargain hunters move in https://seekingalpha.com/news/3517287-pot-stocks-rally-bargain-hunters-move-in?source=tweet\" data-url=\"https://seekingalpha.com/news/3517287-pot-stocks-rally-bargain-hunters-move-in\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>140&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517285\" data-ts=\"1573235611\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517285-mdr-aaxn-watt-and-clvs-among-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MDR, AAXN, WATT and CLVS among midday movers</a></h4><ul><li><strong>Gainers: </strong>Leaf Group (NYSE:<a href='https://seekingalpha.com/symbol/LEAF' title='Leaf Group Ltd.'>LEAF</a>) <font color=\"green\">+40%</font>.</li><li>Clovis Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology, Inc.'>CLVS</a>) <font color=\"green\">+37%</font>.</li><li>RAPT Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/RAPT' title='RAPT Therapeutics, Inc.'>RAPT</a>) <font color=\"green\">+32%</font>.</li><li>Ubiquiti (NYSE:<a href='https://seekingalpha.com/symbol/UI' title='Ubiquiti Inc.'>UI</a>) <font color=\"green\">+34%</font>.</li><li>TrueCar (NASDAQ:<a href='https://seekingalpha.com/symbol/TRUE' title='TrueCar, Inc.'>TRUE</a>) <font color=\"green\">+32%</font>.</li><li>Sientra (NASDAQ:<a href='https://seekingalpha.com/symbol/SIEN' title='Sientra, Inc.'>SIEN</a>) <font color=\"green\">+30%</font>.</li><li>Dermira (NASDAQ:<a href='https://seekingalpha.com/symbol/DERM' title='Dermira, Inc.'>DERM</a>) <font color=\"green\">+28%</font>.</li><li>Axon Enterprise (NASDAQ:<a href='https://seekingalpha.com/symbol/AAXN' title='Axon Enterprise, Inc.'>AAXN</a>) <font color=\"green\">+24%</font>.</li><li>Fulgent Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/FLGT' title='Fulgent Genetics, Inc.'>FLGT</a>) <font color=\"green\">+23%</font>.</li><li>Synthesis Energy Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/SES' title='Synthesis Energy Systems, Inc.'>SES</a>) <font color=\"green\">+22%</font>.</li> <li><strong>Losers: </strong>AnaptysBio (NASDAQ:<a href='https://seekingalpha.com/symbol/ANAB' title='AnaptysBio, Inc.'>ANAB</a>) <font color=\"red\">-72%</font>.</li><li>Red Lion Hotels (NYSE:<a href='https://seekingalpha.com/symbol/RLH' title='Red Lion Hotels Corporation'>RLH</a>) <font color=\"red\">-55%</font>.</li><li>Unit Corporation (NYSE:<a href='https://seekingalpha.com/symbol/UNT' title='Unit Corporation'>UNT</a>) <font color=\"red\">-40%</font>.</li><li>Modine Manufacturing (NYSE:<a href='https://seekingalpha.com/symbol/MOD' title='Modine Manufacturing Company'>MOD</a>) <font color=\"red\">-39%</font>.</li><li>Quorum Health (NYSE:<a href='https://seekingalpha.com/symbol/QHC' title='Quorum Health Corporation'>QHC</a>) <font color=\"red\">-33%</font>.</li><li>Medifast (NYSE:<a href='https://seekingalpha.com/symbol/MED' title='Medifast, Inc.'>MED</a>) <font color=\"red\">-29%</font>.</li><li>Therapix Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/TRPX' title='Therapix Biosciences Ltd.'>TRPX</a>) <font color=\"red\">-27%</font>.</li><li>McDermott International (NYSE:<a href='https://seekingalpha.com/symbol/MDR' title='McDermott International, Inc.'>MDR</a>) <font color=\"red\">-28%</font>.</li><li>NV5 Global (NASDAQ:<a href='https://seekingalpha.com/symbol/NVEE' title='NV5 Global, Inc.'>NVEE</a>) <font color=\"red\">-24%</font>.</li><li>Energous (NASDAQ:<a href='https://seekingalpha.com/symbol/WATT' title='Energous Corporation'>WATT</a>) <font color=\"red\">-22%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3517285\" data-linked=\"MDR, AAXN, WATT and CLVS among midday movers\" data-tweet=\"$LEAF $CLVS $RAPT - MDR, AAXN, WATT and CLVS among midday movers https://seekingalpha.com/news/3517285-mdr-aaxn-watt-and-clvs-among-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3517285-mdr-aaxn-watt-and-clvs-among-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:53 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517284\" data-ts=\"1573235566\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GDOT\" target=\"_blank\">GDOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517284-green-dot-sinks-on-first-look-2020-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Green Dot sinks on first look at 2020 guidance</a></h4><ul><li>Green Dot (NYSE:<a href='https://seekingalpha.com/symbol/GDOT' title='Green Dot Corporation'>GDOT</a>) <font color=\"red\">plunges 21%</font> after preliminary 2020 guidance discussed in its earnings call disappointed investors and analysts.</li><li>CFO Mark Shifke <a href=\"https://seekingalpha.com/article/4304167-green-dot-corporations-gdot-ceo-steve-streit-q3-2019-results-earnings-call-transcript\" target=\"_blank\">doesn't expect</a> \"to guide much more than flat on the top line and perhaps $65M lower year-over-year on adjusted EBITDA\" when the company provides formal 2020 guidance on its February earnings call.</li><li>Cites combination of reduced interest income due to lower rates, about 150 basis point reduction associated with GDOT's renewal of its Walmart MoneyCard contract, higher SG&amp;A expenses for its banking-as-a-service platform, and higher marketing expenses.</li><li>BTIG analyst Mark Palmer<a href=\"http://researchwiseny.btig.com/ResearchLibraryAnalec/DownloadResearch.aspx?E=caabgk-b\" target=\"_blank\"> writes in a note</a> that that implies FY2020 adjusted EBITDA of $175M-$180M vs. consensus of $273.5M.</li><li>He reiterates neutral recommendation.</li><li>Quant rating is <a href=\"https://seekingalpha.com/symbol/GDOT/ratings/quant-ratings\" target=\"_blank\">Very Bearish</a>; Sell-Side average rating is <a href=\"https://seekingalpha.com/symbol/GDOT/ratings/sell-side-ratings\" target=\"_blank\">Bullish</a> (5 Very Bullish, 2 Bullish, 9 Neutral).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3516732-green-dot-eps-beats-0_18-beats-revenue\" target=\"_blank\">Green Dot EPS beats by $0.18, beats on revenue</a> (Nov. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3517284\" data-linked=\"Green Dot sinks on first look at 2020 guidance\" data-tweet=\"$GDOT - Green Dot sinks on first look at 2020 guidance https://seekingalpha.com/news/3517284-green-dot-sinks-on-first-look-2020-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3517284-green-dot-sinks-on-first-look-2020-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517276\" data-ts=\"1573233637\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KDP\" target=\"_blank\">KDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517276-morgan-stanley-still-sees-keurig-dr-pepper-pricey\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley still sees Keurig Dr Pepper as pricey</a></h4><ul><li>Morgan Stanley gives Keurig Dr Pepper (<a href='https://seekingalpha.com/symbol/KDP' title='Keurig Dr Pepper Inc.'>KDP</a> <font color='red'>-1.7%</font>) credit for a solid earnings report driven by the 8.8% organic growth in the beverage concentrate business, but sticks with an Underweight ratings.</li><li>Analyst Dara Mohsenian crunches the numbers: \"Despite solid Q3 results, we remain UW on KDP as we believe KDP valuation looks too elevated in our minds for a company posting ~2.6% organic sales growth YTD vs. PEP/KO in the ~4-5% range, yet post today's stock move it is trading at ~16x CY21e EV/EBITDA, a ~2.5% premium to the average of KO/PEP (or ~14% premium to PEP).\"</li><li>The <a href=\"https://seekingalpha.com/symbol/KDP/ratings/sell-side-ratings\" target=\"_blank\">average sell-side rating</a> of KDP is Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517276\" data-linked=\"Morgan Stanley still sees Keurig Dr Pepper as pricey\" data-tweet=\"$KDP - Morgan Stanley still sees Keurig Dr Pepper as pricey https://seekingalpha.com/news/3517276-morgan-stanley-still-sees-keurig-dr-pepper-pricey?source=tweet\" data-url=\"https://seekingalpha.com/news/3517276-morgan-stanley-still-sees-keurig-dr-pepper-pricey\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517274\" data-ts=\"1573233325\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEX\" target=\"_blank\">TEX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517274-terex-added-to-conviction-buy-list-goldman\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Terex added to Conviction Buy List at Goldman</a></h4><ul><li>Terex (<a href='https://seekingalpha.com/symbol/TEX' title='Terex Corporation'>TEX</a> <font color=\"green\">+6.1%</font>) rallies to its highest level since July after Goldman Sachs <a href=\"https://thefly.com/thestreet/realmoney/index.php/TEXid2990738/TEX-Terex-upgraded-to-Conviction-Buy-from-Sell-at-Goldman-Sachs\" target=\"_blank\">upgrades shares to Buy</a> from Sell with a $37 price target, raised from $25, and adds the name to its Conviction Buy List.</li><li>Goldman analyst Jerry Revich believes TEX's  Aerial Work Platform segment earnings are bottoming in Q4 and that the  \"second derivative has turned\" for used inventories, indicating that  supply-and-demand is re-balancing and thus improving scope for multiple  expansion on mid-cycle earnings.</li><li>TEX's average <a href=\"https://seekingalpha.com/symbol/TEX/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Neutral, its <a href=\"https://seekingalpha.com/symbol/TEX/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors Rating</a> is Bullish, and its <a href=\"https://seekingalpha.com/symbol/TEX/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Bearish.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517274\" data-linked=\"Terex added to Conviction Buy List at Goldman\" data-tweet=\"$TEX - Terex added to Conviction Buy List at Goldman https://seekingalpha.com/news/3517274-terex-added-to-conviction-buy-list-goldman?source=tweet\" data-url=\"https://seekingalpha.com/news/3517274-terex-added-to-conviction-buy-list-goldman\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517272\" data-ts=\"1573233213\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517272-vericity-leads-financial-gainers-uniti-group-and-green-dot-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vericity leads financial gainers; Uniti Group and Green Dot among losers</a></h4><ul><li><b>Gainers:</b> Vericity (VERY) <font color=\"green\">+11%</font>. Camping World Holdings (NYSE:<a href='https://seekingalpha.com/symbol/CWH' title='Camping World Holdings, Inc.'>CWH</a>) <font color=\"green\">+11%</font>. Sirius International Insurance Group (NASDAQ:<a href='https://seekingalpha.com/symbol/SG' title='Sirius International Insurance Group, Ltd.'>SG</a>) <font color=\"green\">+9%</font>. Hallmark Financial Services (NASDAQ:<a href='https://seekingalpha.com/symbol/HALL' title='Hallmark Financial Services, Inc.'>HALL</a>) <font color=\"green\">+9%</font>. Power REIT (NYSEMKT:<a href='https://seekingalpha.com/symbol/PW' title='Power REIT'>PW</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers:</b> Green Dot (NYSE:<a href='https://seekingalpha.com/symbol/GDOT' title='Green Dot Corporation'>GDOT</a>) <font color=\"red\">-21%</font>. Colony Credit Real Estate (NYSE:<a href='https://seekingalpha.com/symbol/CLNC' title='Colony Credit Real Estate, Inc.'>CLNC</a>) <font color=\"red\">-18%</font>. Marcus &amp; Millichap (NYSE:<a href='https://seekingalpha.com/symbol/MMI' title='Marcus & Millichap, Inc.'>MMI</a>) <font color=\"red\">-12%</font>. Impac Mortgage Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/IMH' title='Impac Mortgage Holdings, Inc.'>IMH</a>) <font color=\"red\">-11%</font>. Uniti Group (NASDAQ:<a href='https://seekingalpha.com/symbol/UNIT' title='Uniti Group Inc.'>UNIT</a>) <font color=\"red\">-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517272\" data-linked=\"Vericity leads financial gainers; Uniti Group and Green Dot among losers\" data-tweet=\"$CWH $SG $HALL - Vericity leads financial gainers; Uniti Group and Green Dot among losers https://seekingalpha.com/news/3517272-vericity-leads-financial-gainers-uniti-group-and-green-dot-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3517272-vericity-leads-financial-gainers-uniti-group-and-green-dot-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517269\" data-ts=\"1573232445\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517269-teva-launches-1_5b-debt-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teva launches $1.5B debt offering</a></h4><ul><li>Aimed at rolling over <a href=\"https://seekingalpha.com/pr/17693179-teva-announces-1_5-billion-debt-tender-offers\" target=\"_blank\">three series</a> of outstanding debt due in 2021, Teva Pharmaceutical Industries (<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color=\"green\">+4.5%</font>) launches a $1.5B private offering Euro-denominated Senior Notes.</li><li>Pricing and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517269\" data-linked=\"Teva launches $1.5B debt offering\" data-tweet=\"$TEVA - Teva launches $1.5B debt offering https://seekingalpha.com/news/3517269-teva-launches-1_5b-debt-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3517269-teva-launches-1_5b-debt-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517267\" data-ts=\"1573232329\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517267-dry-bulk-shipping-rates-fall-again\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dry bulk shipping rates fall again</a></h4><ul><li>The Baltic Dry Index fell 3.5% to 1,378 points in London as the downtrend with rates extends.</li><li>The BDI has now fallen for 9 straight sessions.</li><li>Capesize rates were down 3.02% on weaker demand for China-Brazil transport and Panamax rates fell 3.72%.</li><li>Related stocks: Diana Shipping (NYSE:<a href='https://seekingalpha.com/symbol/DSX' title='Diana Shipping Inc.'>DSX</a>), DryShips (NASDAQ:<a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a>), Eagle Bulk Shipping (NASDAQ:<a href='https://seekingalpha.com/symbol/EGLE' title='Eagle Bulk Shipping Inc.'>EGLE</a>), Navios Maritime Holdings (NYSE:<a href='https://seekingalpha.com/symbol/NM' title='Navios Maritime Holdings Inc.'>NM</a>), Navios Maritime Partners (NYSE:<a href='https://seekingalpha.com/symbol/NMM' title='Navios Maritime Partners L.P.'>NMM</a>), Globus Maritime Limited (NASDAQ:<a href='https://seekingalpha.com/symbol/GLBS' title='Globus Maritime Limited'>GLBS</a>), Safe Bulkers (NYSE:<a href='https://seekingalpha.com/symbol/SB' title='Safe Bulkers, Inc.'>SB</a>), Scorpio Bulkers (NYSE:<a href='https://seekingalpha.com/symbol/SALT' title='Scorpio Bulkers Inc.'>SALT</a>), Star Bulk Carriers (NASDAQ:<a href='https://seekingalpha.com/symbol/SBLK' title='Star Bulk Carriers Corp.'>SBLK</a>), Golden Ocean Group Limited (NASDAQ:<a href='https://seekingalpha.com/symbol/GOGL' title='Golden Ocean Group Limited'>GOGL</a>), Seanergy Maritime (NASDAQ:<a href='https://seekingalpha.com/symbol/SHIP' title='Seanergy Maritime Holdings Corp.'>SHIP</a>), EuroDry (NASDAQ:<a href='https://seekingalpha.com/symbol/EDRY' title='EuroDry Ltd.'>EDRY</a>), Genco Shipping &amp; Trading (NYSE:<a href='https://seekingalpha.com/symbol/GNK' title='Genco Shipping & Trading Limited'>GNK</a>).</li> <li>Related ETFs: <a href='https://seekingalpha.com/symbol/SEA' title='Invesco Shipping ETF'>SEA</a>, <a href='https://seekingalpha.com/symbol/BDRY' title='ETF Managers Group Commodity Trust I - Breakwave Dry Bulk Shipping ETF'>BDRY</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3517267\" data-linked=\"Dry bulk shipping rates fall again\" data-tweet=\"$DSX $DRYS $EGLE - Dry bulk shipping rates fall again https://seekingalpha.com/news/3517267-dry-bulk-shipping-rates-fall-again?source=tweet\" data-url=\"https://seekingalpha.com/news/3517267-dry-bulk-shipping-rates-fall-again\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517265\" data-ts=\"1573231890\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ETM\" target=\"_blank\">ETM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517265-entercomplus-17-after-q3-beats-on-organic-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Entercom +17% after Q3 beats on organic growth</a></h4><ul>   <li>Entercom Communications (NYSE:<a href='https://seekingalpha.com/symbol/ETM' title='Entercom Communications Corp.'>ETM</a>) is <font color=\"green\">up 17.1%</font> after its <a href=\"https://seekingalpha.com/news/3517150-entercom-communications-eps-beats-0_01-beats-revenue\" target=\"_blank\">Q3 beat</a>, reclaiming ground it hasn't seen since <a href=\"https://seekingalpha.com/news/3488528-entercom-minus-41-percent-q2-miss-podcast-deals\" target=\"_blank\">tumbling after its August earnings report</a>.</li>    <li>Revenues rose 2% (and just under 3% excluding political revenue for a non-election year) to $386.1M, driven by digital, national and network.</li>    <li>Operating income ticked up to $79.5M from $78.7M. EBITDA, meanwhile, rose 13% to $98M, and adjusted EPS was up 23% year-over-year.</li>    <li>At quarter's end, the company had $1B in senior debt under credit facilities, $325M in second-lien notes and $400M in senior notes. It had $45M in cash on hand.</li>    <li><a href=\"https://seekingalpha.com/pr/17692979-entercom-communications-third-quarter-net-revenues-increase-2-percent\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3517265\" data-linked=\"Entercom +17% after Q3 beats on organic growth\" data-tweet=\"$ETM - Entercom +17% after Q3 beats on organic growth https://seekingalpha.com/news/3517265-entercomplus-17-after-q3-beats-on-organic-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/3517265-entercomplus-17-after-q3-beats-on-organic-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517264\" data-ts=\"1573231879\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TNDM\" target=\"_blank\">TNDM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517264-tandem-diabetes-down-6-on-death-of-t-slim-x2-user\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tandem Diabetes down 6% on death of t:slim X2 user</a></h4><ul><li>Tandem Diabetes Care (<a href='https://seekingalpha.com/symbol/TNDM' title='Tandem Diabetes Care, Inc.'>TNDM</a> <font color=\"red\">-5.9%</font>) is down on almost triple normal volume in apparent reaction to an FDA <a href=\"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/detail.cfm?mdrfoi__id=9256157&amp;pc=OZO\" target=\"_blank\">report </a>on an adverse event (death) related to its t:slim X2 Insulin Pump.</li><li>According the coroner, the person's blood sugar was very low at the time of death.</li><li>No further details are available.</li><li><strong>Update</strong>: In a statement, the company says the death was not caused by a pump malfunction.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517264\" data-linked=\"Tandem Diabetes down 6% on death of t:slim X2 user\" data-tweet=\"$TNDM - Tandem Diabetes down 6% on death of t:slim X2 user https://seekingalpha.com/news/3517264-tandem-diabetes-down-6-on-death-of-t-slim-x2-user?source=tweet\" data-url=\"https://seekingalpha.com/news/3517264-tandem-diabetes-down-6-on-death-of-t-slim-x2-user\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517260\" data-ts=\"1573230780\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QHC\" target=\"_blank\">QHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517260-guidance-cut-pressures-quorum-health-down-37\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Guidance cut pressures Quorum Health, down 37%</a></h4><ul><li>Thinly traded nano cap Quorum Health (<a href='https://seekingalpha.com/symbol/QHC' title='Quorum Health Corporation'>QHC</a> <font color=\"red\">-37%</font>) is down on more than a 5x surge in volume, albeit on turnover of only 909K shares,  on the heels of its <a href=\"https://seekingalpha.com/pr/17692484-quorum-health-corporation-announces-third-quarter-2019-results\" target=\"_blank\">Q3 report</a> released after the close yesterday that included another guidance cut. Highlights:</li><li>Revenues: $419.9M (-8.8%).</li><li>Net loss: ($75.9M) (-40.8%); loss/share: ($2.52) (-36.2%); non-GAAP EBITDA: $13.7M (-59.8%).</li><li>Cash flow ops: $25.2M (-11.3%).</li><li><strong>2019 guidance</strong>: Same-facility revenue: $1.525B - 1.575B from $1,550M - 1,600M; same-facility non-GAAP EBITDA: $140M - 155M from $160M - 180M.</li><li>The company also <a href=\"https://seekingalpha.com/news/3489603-quorum-health-17-percent-q2-miss-softer-revenue-outlook\" target=\"_blank\">cut guidance</a> last quarter.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3516925-quorum-health-eps-misses-0_44-beats-revenue\" target=\"_blank\">Quorum Health EPS misses by $0.44, beats on revenue</a> (Nov. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3517260\" data-linked=\"Guidance cut pressures Quorum Health, down 37%\" data-tweet=\"$QHC - Guidance cut pressures Quorum Health, down 37% https://seekingalpha.com/news/3517260-guidance-cut-pressures-quorum-health-down-37?source=tweet\" data-url=\"https://seekingalpha.com/news/3517260-guidance-cut-pressures-quorum-health-down-37\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:33 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517259\" data-ts=\"1573230763\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSP\" target=\"_blank\">SSP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517259-scrippsplus-6_8-after-q3s-broad-revenue-gains\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Scripps +6.8% after Q3&#39;s broad revenue gains</a></h4><ul>   <li>E.W. Scripps (NASDAQ:<a href='https://seekingalpha.com/symbol/SSP' title='The E.W. Scripps Company'>SSP</a>) is <font color=\"green\">up 6.8%</font> after topping revenue expectations with its <a href=\"https://seekingalpha.com/news/3517122-e-w-scripps-eps-misses-0_14-beats-revenue\" target=\"_blank\">Q3 earnings</a> this morning, with significant national gains matching increases in local revenues.</li>    <li>Overall revenue rose by 15.5% to $349.8M.</li>    <li>The company swung to a loss from continuing operations of $21.9M from a year-ago gain of $20M; the current-year loss was exacerbated by $12.6M due to acquisition/integration costs.</li>    <li>Revenue by segment: Local Media, $252.4M (up 9.4%); National Media, $97.2M (up 35.5%).</li>   <li>Profit by segment: Local Media, $49.7M (down 26.3%); National Media, $5.3M (up 85%).</li>    <li>Cash and equivalents came to $86.5M, against total debt of $1.98B.</li>    <li>For Q4, it's guiding to Local Media revenue (pro forma) falling in the low 20% range, and National Media of $100M-$105M. It expects capital expenditures (excluding repack) of about $10M.</li>    <li><a href=\"https://seekingalpha.com/pr/17692882-scripps-reports-third-quarter-2019-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3517259\" data-linked=\"Scripps +6.8% after Q3&#39;s broad revenue gains\" data-tweet=\"$SSP - Scripps +6.8% after Q3&#39;s broad revenue gains https://seekingalpha.com/news/3517259-scrippsplus-6_8-after-q3s-broad-revenue-gains?source=tweet\" data-url=\"https://seekingalpha.com/news/3517259-scrippsplus-6_8-after-q3s-broad-revenue-gains\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:32 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517258\" data-ts=\"1573230299\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517258-ubs-cuts-micron-on-nand-pricing-muminus-1_5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UBS cuts Micron on NAND pricing; MU -1.5%</a></h4><ul><li>UBS analyst Timothy Arcuri cuts his Micron (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology, Inc.'>MU</a>) earnings and revenue estimates for FY20 and FY21.</li><li>Arcuri is taking \"a more cautious view on NAND pricing\" through next year, and the \"reality of another step-down could still be a hurdle the stock needs to clear.\"</li><li>UBS has a Neutral rating and $47 target on Micron. The company has a Bullish average <a href=\"https://seekingalpha.com/symbol/MU/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li><li>Micron shares are <font color=\"red\">down 1.5%</font> to $47.66.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517258\" data-linked=\"UBS cuts Micron on NAND pricing; MU -1.5%\" data-tweet=\"$MU - UBS cuts Micron on NAND pricing; MU -1.5% https://seekingalpha.com/news/3517258-ubs-cuts-micron-on-nand-pricing-muminus-1_5?source=tweet\" data-url=\"https://seekingalpha.com/news/3517258-ubs-cuts-micron-on-nand-pricing-muminus-1_5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>68&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517257\" data-ts=\"1573230091\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MOD\" target=\"_blank\">MOD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517257-modine-manufacturing-plummets-to-three-year-low\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Modine Manufacturing plummets to three-year low</a></h4><ul><li>Modine Manufacturing (<a href='https://seekingalpha.com/symbol/MOD' title='Modine Manufacturing Company'>MOD</a> <font color='red'>-38%</font>) sinks after Q3 results disappoint and guidance is set lower.</li><li>\"While we did see double-digit top-line growth in our BHVAC business, our VTS and CIS segments both experienced larger than expected declines in customer orders that will negatively impact our revenues and earnings in H2 of the year,\" warns Modine CEO Thomas Burke.</li><li>Modine expects full-year EPS of $0.75 to $0.90 vs. a prior view for $1.35 to $1.50 and $1.31 consensus.</li><li>On Wall Street, Dougherty cut its rating on Modine to Neutral from Buy.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3516859-modine-manufacturing-eps-misses-0_12-misses-revenue\" target=\"_blank\">Modine Manufacturing EPS misses by $0.12, misses on revenue</a> (Nov. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3517257\" data-linked=\"Modine Manufacturing plummets to three-year low\" data-tweet=\"$MOD - Modine Manufacturing plummets to three-year low https://seekingalpha.com/news/3517257-modine-manufacturing-plummets-to-three-year-low?source=tweet\" data-url=\"https://seekingalpha.com/news/3517257-modine-manufacturing-plummets-to-three-year-low\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517255\" data-ts=\"1573229780\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIEN\" target=\"_blank\">SIEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517255-sientra-up-26-on-q3-sales-ramp-guidance-boost\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sientra up 26% on Q3 sales ramp, guidance boost</a></h4><ul><li>Sientra (<a href='https://seekingalpha.com/symbol/SIEN' title='Sientra, Inc.'>SIEN</a> <font color=\"green\">+25.7%</font>) is up on triple normal volume after its <a href=\"https://seekingalpha.com/pr/17692235-sientra-reports-third-quarter-2019-financial-results\" target=\"_blank\">Q3 report</a> released after the close yesterday. Highlights:</li><li>Sales: $22.4M (+33%); Breast Products: $12.6M (+47%); miraDry: $9.8M (+18%).</li><li>Net loss: ($22.4M) (-9%); loss/share: ($0.45) (+38%).</li><li>Cash consumption (9 mo.): ($73.5M) (-78%).</li><li><strong>2019 guidance</strong>: Sales: $82.5M - 83.5M from $79.0M - 83.0M; Breast Product sales: $46.0M - 46.5M; miraDry sales: $36.5M - 37.0M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3516653-sientra-eps-beats-0_02-beats-revenue\" target=\"_blank\">Sientra EPS beats by $0.02, beats on revenue</a> (Nov. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3517255\" data-linked=\"Sientra up 26% on Q3 sales ramp, guidance boost\" data-tweet=\"$SIEN - Sientra up 26% on Q3 sales ramp, guidance boost https://seekingalpha.com/news/3517255-sientra-up-26-on-q3-sales-ramp-guidance-boost?source=tweet\" data-url=\"https://seekingalpha.com/news/3517255-sientra-up-26-on-q3-sales-ramp-guidance-boost\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517256\" data-ts=\"1573229718\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENG\" target=\"_blank\">ENG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517256-englobal-wins-20m-plus-deal-to-supply-modular-hydrogen-plant\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ENGlobal wins $20M-plus deal to supply modular hydrogen plant</a></h4><ul><li>ENGlobal (<a href='https://seekingalpha.com/symbol/ENG' title='ENGlobal Corporation'>ENG</a> <font color='green'>+27.1%</font>) rockets higher on news it signed a <a href=\"https://seekingalpha.com/pr/17692798-englobal-signs-20-million-plus-contract-supply-modular-hydrogen-plant-renewable-diesel\" target=\"_blank\">contract valued at more than $20M</a> to supply process  modules that will be used to construct an unnamed complete hydrogen production  facility.</li><li>ENG says the total sum expected under the deal could exceed the company's $25.8M revenues for all of H1 2019, adding that the scope of work could be increased over the 18-month  project duration.</li><li>ENG says its compact plant will be a major component of a grass roots  renewable diesel facility with an expected maximum production of 10K bbl/day of renewable diesel.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517256\" data-linked=\"ENGlobal wins $20M-plus deal to supply modular hydrogen plant\" data-tweet=\"$ENG - ENGlobal wins $20M-plus deal to supply modular hydrogen plant https://seekingalpha.com/news/3517256-englobal-wins-20m-plus-deal-to-supply-modular-hydrogen-plant?source=tweet\" data-url=\"https://seekingalpha.com/news/3517256-englobal-wins-20m-plus-deal-to-supply-modular-hydrogen-plant\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517251\" data-ts=\"1573229129\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALB\" target=\"_blank\">ALB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517251-overvalued-albemarle-cut-to-sell-equivalent-j-p-morgan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">&#39;Overvalued&#39; Albemarle cut to Sell equivalent at J.P. Morgan</a></h4><ul><li>Albemarle (<a href='https://seekingalpha.com/symbol/ALB' title='Albemarle Corporation'>ALB</a> <font color=\"red\">-5.9%</font>) surrenders yesterday's gains as J.P. Morgan <a href=\"https://thefly.com/thestreet/realmoney/index.php/ALBid2990954/ALB-JPMorgan-downgrades-overvalued-Albemarle-to-Underweight-from-Neutral\" target=\"_blank\">downgrades</a> shares to Underweight from Neutral with a $60 price target, cut from $68, with analyst Jeffrey Zekauskas saying ALB is overvalued trading at 11.2x estimated FY 2020 EBITDA.</li><li>Zekauskas believes the growth rate of global electric vehicles is slowing and lithium supply is accelerating, noting that prices in the lithium industry have declined sharply due to oversupply conditions.</li><li>The analyst also thinks ALB's long-term contracts likely will be renegotiated downward.</li><li>ALB's average <a href=\"https://seekingalpha.com/symbol/ALB/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> and <a href=\"https://seekingalpha.com/symbol/ALB/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors Rating</a> both are Bullish, while its <a href=\"https://seekingalpha.com/symbol/ALB/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Bearish.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517251\" data-linked=\"&#39;Overvalued&#39; Albemarle cut to Sell equivalent at J.P. Morgan\" data-tweet=\"$ALB - &#39;Overvalued&#39; Albemarle cut to Sell equivalent at J.P. Morgan https://seekingalpha.com/news/3517251-overvalued-albemarle-cut-to-sell-equivalent-j-p-morgan?source=tweet\" data-url=\"https://seekingalpha.com/news/3517251-overvalued-albemarle-cut-to-sell-equivalent-j-p-morgan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>56&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517246\" data-ts=\"1573228923\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517246-dermira-leads-healthcare-gainers-therapix-biosciences-and-neovasc-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dermira leads healthcare gainers, Therapix Biosciences and Neovasc among losers</a></h4><ul><li><b>Gainers:</b> Dermira (NASDAQ:<a href='https://seekingalpha.com/symbol/DERM' title='Dermira, Inc.'>DERM</a>) <font color=\"green\">+26%</font>. Sientra (NASDAQ:<a href='https://seekingalpha.com/symbol/SIEN' title='Sientra, Inc.'>SIEN</a>) <font color=\"green\">+24%</font>. Fulgent Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/FLGT' title='Fulgent Genetics, Inc.'>FLGT</a>) <font color=\"green\">+21%</font>. Clovis Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology, Inc.'>CLVS</a>) <font color=\"green\">+21%</font>. Misonix (NASDAQ:<a href='https://seekingalpha.com/symbol/MSON' title='Misonix, Inc.'>MSON</a>) <font color=\"green\">+15%</font>.</li><li><b>Losers:</b> AnaptysBio (NASDAQ:<a href='https://seekingalpha.com/symbol/ANAB' title='AnaptysBio, Inc.'>ANAB</a>) <font color=\"red\">-70%</font>. Quorum Health (NYSE:<a href='https://seekingalpha.com/symbol/QHC' title='Quorum Health Corporation'>QHC</a>) <font color=\"red\">-38%</font>. Therapix Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/TRPX' title='Therapix Biosciences Ltd.'>TRPX</a>) <font color=\"red\">-24%</font>. EyePoint Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/EYPT' title='EyePoint Pharmaceuticals, Inc.'>EYPT</a>) <font color=\"red\">-14%</font>. Neovasc (NASDAQ:<a href='https://seekingalpha.com/symbol/NVCN' title='Neovasc Inc.'>NVCN</a>) <font color=\"red\">-14%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517246\" data-linked=\"Dermira leads healthcare gainers, Therapix Biosciences and Neovasc among losers\" data-tweet=\"$DERM $SIEN $FLGT - Dermira leads healthcare gainers, Therapix Biosciences and Neovasc among losers https://seekingalpha.com/news/3517246-dermira-leads-healthcare-gainers-therapix-biosciences-and-neovasc-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3517246-dermira-leads-healthcare-gainers-therapix-biosciences-and-neovasc-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517245\" data-ts=\"1573228498\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TCON\" target=\"_blank\">TCON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517245-tracon-pharma-reverse-splits-shares-1-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tracon Pharma reverse splits shares 1:10</a></h4><ul><li>TRACON Pharmaceuticals (<a href='https://seekingalpha.com/symbol/TCON' title='TRACON Pharmaceuticals, Inc.'>TCON</a> <font color=\"red\">-0.7%</font>) executed a 1:10 reverse split of its common stock after the close yesterday. Post-split trading began today.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517245\" data-linked=\"Tracon Pharma reverse splits shares 1:10\" data-tweet=\"$TCON - Tracon Pharma reverse splits shares 1:10 https://seekingalpha.com/news/3517245-tracon-pharma-reverse-splits-shares-1-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3517245-tracon-pharma-reverse-splits-shares-1-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517244\" data-ts=\"1573228352\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNST\" target=\"_blank\">MNST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517244-monster-expects-to-ride-out-coke-energy-competition\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Monster expects to ride out Coke Energy competition</a></h4><ul><li>Monster Beverage (<a href='https://seekingalpha.com/symbol/MNST' title='Monster Beverage Corporation'>MNST</a> <font color='green'>+4.4%</font>) shoots higher after a solid Q3 earnings report.</li><li>Today's rally could also be tied in part to positive comments by Monster execs on the earnings call on the impact of Coke Energy, according to Morgan Stanley</li><li>\"MNST was dismissive of the market share risk from Coke Energy, indicating in the international markets where Coke Energy was launched reached modest market share levels (declining sequentially in certain markets) and it did not impact Monster sales growth,\" notes analyst Dara Mohsenian.</li><li><a href=\"https://seekingalpha.com/article/4304132-monster-beverage-corporations-mnst-ceo-rodney-sacks-q3-2019-results-earnings-call-transcript\" target=\"_blank\">Monster Beverage earnings call transcript</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3516713-monster-beverage-tops-estimates-dials-buybacks\" target=\"_blank\">Monster Beverage tops estimates, dials up more buybacks</a> (Nov. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3517244\" data-linked=\"Monster expects to ride out Coke Energy competition\" data-tweet=\"$MNST - Monster expects to ride out Coke Energy competition https://seekingalpha.com/news/3517244-monster-expects-to-ride-out-coke-energy-competition?source=tweet\" data-url=\"https://seekingalpha.com/news/3517244-monster-expects-to-ride-out-coke-energy-competition\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517242\" data-ts=\"1573228281\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DBX\" target=\"_blank\">DBX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517242-analyst-sees-dbx-inflection-point\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analyst sees DBX &#39;inflection point&#39;</a></h4><ul><li>Nomura maintains its Buy rating on Dropbox (NASDAQ:<a href='https://seekingalpha.com/symbol/DBX' title='Dropbox, Inc.'>DBX</a>) and raises the target from $25 to $27 after yesterday's <a href=\"https://seekingalpha.com/news/3516669-dropbox-beats-q3-estimates-grows-paying-users\" target=\"_blank\">Q3 beats</a>.</li><li>The firm notes the results showed the \"first ever revenue re-acceleration as a public company,\" representing a \"significant inflection point.\"</li><li>Nomura continues to see upside to consensus estimates for three to five quarters, \"even if net adds are cut in half.\"</li><li>Canaccord Genuity (Buy, $35) says DBX \"could be an epic stock\" with successful execution.</li><li>The firm notes the upside in net customer adds and ARPU and says the trends might convince investors \"that the fear of a death spiral growth deceleration is overwrought.\"</li><li>Dropbox shares are <font color=\"red\">down 5.6%</font> to $19.79. The company has a Bullish average <a href=\"https://seekingalpha.com/symbol/DBX/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517242\" data-linked=\"Analyst sees DBX &#39;inflection point&#39;\" data-tweet=\"$DBX - Analyst sees DBX &#39;inflection point&#39; https://seekingalpha.com/news/3517242-analyst-sees-dbx-inflection-point?source=tweet\" data-url=\"https://seekingalpha.com/news/3517242-analyst-sees-dbx-inflection-point\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517240\" data-ts=\"1573228047\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCG\" target=\"_blank\">PCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517240-pg-and-es-insurance-claims-payout-plan-hurting-bankruptcy-talks-wsj\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PG&amp;E&#39;s insurance claims payout plan hurting bankruptcy talks - WSJ</a></h4><ul><li>An $11B settlement of insurance claims tied to PG&amp;E's (<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a> <font color=\"green\">+4.7%</font>) alleged responsibility for California wildfires is emerging as a <a href=\"https://www.wsj.com/articles/pg-e-plan-to-pay-insurance-claims-in-cash-hurts-bankruptcy-talks-11573222528\" target=\"_blank\">barrier to a potentially broader deal</a> to end the utility's  bankruptcy, as wildfire victims seek better treatment by PG&amp;E, <em>WSJ</em> reports.</li><li>If approved by the court overseeing PG&amp;E's bankruptcy, the deal  could tie up much of the free cash the company will have as it exits  bankruptcy; some of the cash would go directly to insurance carriers, and some would go to hedge funds that bought insurers' claims against PG&amp;E at  discounts.</li><li>Meanwhile, wildfire victims would be more likely to receive shares in the  restructured company as compensation rather than cash.</li><li>According to the report, that prospect is not sitting well with lawyers for fire victims, who  already are being pressured to take less than the $54B they  believe their clients are owed.</li><li>Market participants also are said to question  whether PG&amp;E can afford to stick with the cash payout for claims  when the utility may be swamped with yet more wildfire damages.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517240\" data-linked=\"PG&amp;E&#39;s insurance claims payout plan hurting bankruptcy talks - WSJ\" data-tweet=\"$PCG - PG&amp;E&#39;s insurance claims payout plan hurting bankruptcy talks - WSJ https://seekingalpha.com/news/3517240-pg-and-es-insurance-claims-payout-plan-hurting-bankruptcy-talks-wsj?source=tweet\" data-url=\"https://seekingalpha.com/news/3517240-pg-and-es-insurance-claims-payout-plan-hurting-bankruptcy-talks-wsj\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517239\" data-ts=\"1573227850\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RLH\" target=\"_blank\">RLH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517239-red-lion-hotels-sinks-to-10-year-low\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Red Lion Hotels sinks to 10-year low</a></h4><ul><li>Red Lion Hotels (NYSE:<a href='https://seekingalpha.com/symbol/RLH' title='Red Lion Hotels Corporation'>RLH</a>) is <font color=\"red\">down 55%</font> and traded as low as $2.76 earlier in the session.</li><li>The company reported a larger Q3 loss than anticipated and announced the resignation of CEO Greg Mount.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3517102-red-lion-hotels-eps-misses-0_26-misses-revenue\" target=\"_blank\">Red Lion Hotels EPS misses by $0.26, misses on revenue</a> (Nov. 8)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3517113-red-lion-hotel-loses-ceo\" target=\"_blank\">Red Lion Hotel loses its CEO</a> (Nov. 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3517239\" data-linked=\"Red Lion Hotels sinks to 10-year low\" data-tweet=\"$RLH - Red Lion Hotels sinks to 10-year low https://seekingalpha.com/news/3517239-red-lion-hotels-sinks-to-10-year-low?source=tweet\" data-url=\"https://seekingalpha.com/news/3517239-red-lion-hotels-sinks-to-10-year-low\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517238\" data-ts=\"1573227806\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FGEN\" target=\"_blank\">FGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517238-fibrogen-down-6-despite-positive-roxadustat-date-in-late-stage-ckd-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FibroGen down 6% despite positive roxadustat date in late-stage CKD study</a></h4><ul><li>A Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02052310?intr=Roxadustat&amp;phase=2&amp;draw=2&amp;rank=9\" target=\"_blank\">HIMALAYAS</a>, evaluating FibroGen's (<a href='https://seekingalpha.com/symbol/FGEN' title='FibroGen, Inc.'>FGEN</a> <font color=\"red\">-6%</font>) roxadustat in chronic kidney disease &#40;CKD&#41; patients who recently initiated dialysis <a href=\"https://seekingalpha.com/pr/17692400-fibrogen-presents-phase-3-efficacy-safety-results-roxadustat-versus-epoetin-alfa-treatment\" target=\"_blank\">met both primary endpoints</a>. The data were presented at the American Society of Nephrology Kidney Week in Washington, DC.</li><li>The open-label study randomized participants 1:1 to receive either roxadustat or epoetin alfa (originally marketed by Amgen under the brand name Epogen) for up to 4.4 years (mean duration of treatment was 1.8 years).</li><li>Results showed that treatment with roxadustat increased mean hemoglobin levels from 8.4 g/dL to 11.0 g/dL compared to an increase from 8.4 g/dL to 10.8 g/dL for epoetin alfa demonstrating its non-inferiority (no worse than).</li><li>Roxadustat was also non-inferior to epoetin alfa in terms of the proportion of patients achieving a hemoglobin response during the first 24 weeks of treatment (88.2% vs. 84.4%).</li><li>Patients receiving roxadustat also required less monthly intravenous iron on average.</li><li>On the safety front, the most frequent roxadustat-related adverse events were hypertension, diarrhea and muscle spasms.</li><li>Collaboration partner AstraZeneca (<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca PLC'>AZN</a> <font color=\"red\">-0.2%</font>) will be presenting data from two Phase 3s, OLYMPUS and ROCKIES, assessing roxadustat for the treatment of anemia in non-dialysis and dialysis-dependent CKD patients at the meeting.</li><li>The stock remains under pressure from a <a href=\"https://seekingalpha.com/news/3513624-fibrogen-6-percent-bearish-plainview-report\" target=\"_blank\">bearish report</a> from Plainview published on Monday. Share have lost <font color=\"red\">11%</font> of their value since then.</li><li>Related ticker: Astellas Pharma (<a href='https://seekingalpha.com/symbol/ALPMY' title='Astellas Pharma Inc.'>OTCPK:ALPMY</a> <font color=\"red\">-1.2%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3517238\" data-linked=\"FibroGen down 6% despite positive roxadustat date in late-stage CKD study\" data-tweet=\"$FGEN $AZN $ALPMY - FibroGen down 6% despite positive roxadustat date in late-stage CKD study https://seekingalpha.com/news/3517238-fibrogen-down-6-despite-positive-roxadustat-date-in-late-stage-ckd-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3517238-fibrogen-down-6-despite-positive-roxadustat-date-in-late-stage-ckd-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517237\" data-ts=\"1573227179\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517237-mall-stocks-follow-gap-lower\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mall stocks follow Gap lower</a></h4><ul><li>Apparel store stocks are lower on the day after Gap reset guidance dramatically lower.</li><li>Notable decliners include J. Jill &lt;JILL&gt;&gt;, Abercrombie &amp; Fitch (<a href='https://seekingalpha.com/symbol/ANF' title='Abercrombie & Fitch Co.'>ANF</a> <font color=\"red\">-3.5%</font>), Express (<a href='https://seekingalpha.com/symbol/EXPR' title='Express, Inc.'>EXPR</a> <font color=\"red\">-2.9%</font>), L Brands (<a href='https://seekingalpha.com/symbol/LB' title='L Brands, Inc.'>LB</a> <font color=\"red\">-3.3%</font>), American Eagle Outfitters (<a href='https://seekingalpha.com/symbol/AEO' title='American Eagle Outfitters, Inc.'>AEO</a> <font color=\"red\">-2.7%</font>), Guess (<a href='https://seekingalpha.com/symbol/GES' title='Guess&#39;, Inc.'>GES</a> <font color=\"red\">-2.3%</font>), Urban Outfitters (<a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a> <font color=\"red\">-1.9%</font>) and Buckle (<a href='https://seekingalpha.com/symbol/BKE' title='The Buckle, Inc.'>BKE</a> <font color=\"red\">-2.7%</font>).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3516738-gap-minus-7-percent-slashing-guidance-ceo-exit\" target=\"_blank\">Gap -7% after slashing guidance and CEO exit</a> (Nov. 7)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3517199-gap-minus-10-percent-investors-puzzle-new-direction\" target=\"_blank\">Gap -10% as investors puzzle over new direction</a> (Nov. 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3517237\" data-linked=\"Mall stocks follow Gap lower\" data-tweet=\"$ANF $EXPR $LB - Mall stocks follow Gap lower https://seekingalpha.com/news/3517237-mall-stocks-follow-gap-lower?source=tweet\" data-url=\"https://seekingalpha.com/news/3517237-mall-stocks-follow-gap-lower\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517233\" data-ts=\"1573226164\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHUY\" target=\"_blank\">CHUY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517233-chuys-sizzles-after-comp-sales-impress\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chuy&#39;s sizzles after comp sales impress</a></h4><ul><li>Chuy's Holdings (<a href='https://seekingalpha.com/symbol/CHUY' title='Chuy&#39;s Holdings, Inc.'>CHUY</a> <font color='green'>+15.2%</font>) rallies after reporting comparable sales increased 2.6% in Q3.</li><li>A 4.5% jump in average check during the quarter offset a 1.9% decline in traffic. Off-premise sales were up 13%.</li><li>Looking ahead, the restaurant chain expects full-year comparable sales growth of 2.0% to 2.5% vs. a prior view for +1.5 to +2.5% and +2.4% consensus.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3516805-chuys-eps-beats-0_05-beats-revenue\" target=\"_blank\">Chuy's EPS beats by $0.05, beats on revenue</a> (Nov. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3517233\" data-linked=\"Chuy&#39;s sizzles after comp sales impress\" data-tweet=\"$CHUY - Chuy&#39;s sizzles after comp sales impress https://seekingalpha.com/news/3517233-chuys-sizzles-after-comp-sales-impress?source=tweet\" data-url=\"https://seekingalpha.com/news/3517233-chuys-sizzles-after-comp-sales-impress\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517232\" data-ts=\"1573226100\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BE\" target=\"_blank\">BE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517232-bloom-energy-blossoms-in-early-trade-after-q3-beat-analyst-praise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bloom Energy blossoms in early trade after Q3 beat, analyst praise</a></h4><ul><li>Bloom Energy (<a href='https://seekingalpha.com/symbol/BE' title='Bloom Energy Corporation'>BE</a> <font color=\"green\">+8.4%</font>) opens with strong gains after beating <a href=\"https://seekingalpha.com/news/3516972-bloom-energy-slides-revenues-flat-q-q-immelt-named-board\" target=\"_blank\">Q3 earnings</a> expectations, and at least three Tier 1 research firms are <a href=\"https://twitter.com/thenotablecalls/status/1192801548998500353\" target=\"_blank\">calling for a bottom in the stock</a>, according to Notable Calls.</li><li>J.P. Morgan maintains its Overweight rating and $12 price target on BE, saying \"management's improved tone\" on the <a href=\"https://seekingalpha.com/article/4304175-bloom-energy-corporation-ceo-kr-sridhar-q3-2019-results-earnings-call-transcript\" target=\"_blank\">Q3 earnings conference call</a> should help the stock recover some of the losses suffered since the Q2 earnings call.</li><li>\"Management tone showed a marked improvement,\" JPM writes, \"particularly with regard to the high-margin California market where recent wildfires and electric grid outages have resulted in a surge in customer interest that could add to backlog in FY20 and revenue in FY21 and beyond.\"</li><li>BE's average <a href=\"https://seekingalpha.com/symbol/BE/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Bullish, but its <a href=\"https://seekingalpha.com/symbol/BE/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors Rating</a> is Bearish and its <a href=\"https://seekingalpha.com/symbol/BE/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Very Bearish.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517232\" data-linked=\"Bloom Energy blossoms in early trade after Q3 beat, analyst praise\" data-tweet=\"$BE - Bloom Energy blossoms in early trade after Q3 beat, analyst praise https://seekingalpha.com/news/3517232-bloom-energy-blossoms-in-early-trade-after-q3-beat-analyst-praise?source=tweet\" data-url=\"https://seekingalpha.com/news/3517232-bloom-energy-blossoms-in-early-trade-after-q3-beat-analyst-praise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517231\" data-ts=\"1573226025\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRIP\" target=\"_blank\">TRIP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517231-tripadvisorminus-2_2-analysts-weigh-q3-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TripAdvisor -2.2% as analysts weigh Q3 miss</a></h4><ul>    <li>TripAdvisor (NASDAQ:<a href='https://seekingalpha.com/symbol/TRIP' title='TripAdvisor, Inc.'>TRIP</a>) is <font color=\"red\">2.2% lower</font> after its <a href=\"https://seekingalpha.com/news/3515871-tripadvisor-reports-downside-q3-trip-com-partnership\" target=\"_blank\">Q3 results</a> disappointed analysts.</li>    <li>JPMorgan cut the shares to Underweight from Neutral and set its price target to $28, now implying 10% downside.</li>    <li>And UBS maintained its Neutral rating but cut its target to $34 from $40.</li>    <li>Overall, the sell side is <a href=\"https://seekingalpha.com/symbol/TRIP/ratings/sell-side-ratings\" target=\"_blank\">Neutral on the stock</a>. <a href=\"https://seekingalpha.com/symbol/TRIP/ratings/author-ratings\" target=\"_blank\">Seeking Alpha authors are Bullish</a>, and it has a <a href=\"https://seekingalpha.com/symbol/TRIP/ratings/quant-ratings\" target=\"_blank\">Quant Rating of Very Bearish</a>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3517231\" data-linked=\"TripAdvisor -2.2% as analysts weigh Q3 miss\" data-tweet=\"$TRIP - TripAdvisor -2.2% as analysts weigh Q3 miss https://seekingalpha.com/news/3517231-tripadvisorminus-2_2-analysts-weigh-q3-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3517231-tripadvisorminus-2_2-analysts-weigh-q3-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517227\" data-ts=\"1573225565\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRPX\" target=\"_blank\">TRPX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517227-therapix-down-23-after-merger-talks-nixed\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Therapix down 23% after merger talks nixed</a></h4><ul><li>Thinly traded nano cap Therapix Biosciences (<a href='https://seekingalpha.com/symbol/TRPX' title='Therapix Biosciences Ltd.'>TRPX</a> <font color=\"red\">-22.9%</font>) is down on more than double normal volume, a modest 134K shares, after <a href=\"https://seekingalpha.com/pr/17692471-therapix-biosciences-destiny-biosciences-global-corp-mutually-decide-discontinue-negotiations\" target=\"_blank\">announcing </a>that merger negotiations with Destiny Biosciences Global Corp. have been terminated by mutual agreement.</li><li>The companies inked a Letter of Intent in July which specified a deadline of October 31 to complete the merger agreement before abandoning the effort.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517227\" data-linked=\"Therapix down 23% after merger talks nixed\" data-tweet=\"$TRPX - Therapix down 23% after merger talks nixed https://seekingalpha.com/news/3517227-therapix-down-23-after-merger-talks-nixed?source=tweet\" data-url=\"https://seekingalpha.com/news/3517227-therapix-down-23-after-merger-talks-nixed\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517221\" data-ts=\"1573224976\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CFMS\" target=\"_blank\">CFMS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517221-conformis-up-6-on-fda-nod-for-new-hip-replacement-system\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Conformis up 6% on FDA nod for new hip replacement system</a></h4><ul><li>Conformis (<a href='https://seekingalpha.com/symbol/CFMS' title='Conformis, Inc.'>CFMS</a> <font color=\"green\">+6.1%</font>) <a href=\"https://seekingalpha.com/pr/17692412-conformis-announces-fda-clearance-full-commercial-launch-next-generation-hip-system-2019\" target=\"_blank\">announces </a>FDA clearance of its next-generation 3D-designed Conformis Hip System that, it says, incorporates improvements based on surgeon feedback after 400+ surgeries that began in July 2018.</li><li>Full commercial launch is underway.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517221\" data-linked=\"Conformis up 6% on FDA nod for new hip replacement system\" data-tweet=\"$CFMS - Conformis up 6% on FDA nod for new hip replacement system https://seekingalpha.com/news/3517221-conformis-up-6-on-fda-nod-for-new-hip-replacement-system?source=tweet\" data-url=\"https://seekingalpha.com/news/3517221-conformis-up-6-on-fda-nod-for-new-hip-replacement-system\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517222\" data-ts=\"1573224900\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517222-hp-offered-to-purchase-xerox-cnbc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HP offered to purchase Xerox - CNBC</a></h4><ul><li>HP (<a href='https://seekingalpha.com/symbol/HPQ' title='HP Inc.'>HPQ</a> <font color=\"red\">-1%</font>) held detailed talks to purchase Xerox (<a href='https://seekingalpha.com/symbol/XRX' title='Xerox Holdings Corporation'>XRX</a> <font color=\"green\">+2.7%</font>) within the past two months, according to CNBC's David Faber.</li><li>The talks ended when HP asked for more time to conduct due diligence.</li><li>HP's response to Xerox's combination bid could take a couple of weeks, according to Faber's sources.</li><li>Yesterday, CNBC sources said Xerox <a href=\"https://seekingalpha.com/news/3516424-xerox-offering-22-share-hp-cnbc\" target=\"_blank\">plans to offer</a> $22/share in a combination of cash and stock.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517222\" data-linked=\"HP offered to purchase Xerox - CNBC\" data-tweet=\"$HPQ $XRX - HP offered to purchase Xerox - CNBC https://seekingalpha.com/news/3517222-hp-offered-to-purchase-xerox-cnbc?source=tweet\" data-url=\"https://seekingalpha.com/news/3517222-hp-offered-to-purchase-xerox-cnbc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517219\" data-ts=\"1573224438\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYTK\" target=\"_blank\">CYTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517219-cytokinetics-prices-convertible-debt-offering-shares-down-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cytokinetics prices convertible debt offering; shares down 2%</a></h4><ul><li>Cytokinetics (<a href='https://seekingalpha.com/symbol/CYTK' title='Cytokinetics, Incorporated'>CYTK</a> <font color=\"red\">-1.5%</font>) <a href=\"https://seekingalpha.com/pr/17692862-cytokinetics-announces-pricing-public-offering-convertible-senior-notes\" target=\"_blank\">prices </a>its upsized $120M (from $100M) offering of 4.00% convertible senior notes due 2026 at par.</li><li>The initial conversion rate will be 94.7811 common shares per $1,000 principal amount of the notes (~$10.55/share).</li><li>Closing date is November 13.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517219\" data-linked=\"Cytokinetics prices convertible debt offering; shares down 2%\" data-tweet=\"$CYTK - Cytokinetics prices convertible debt offering; shares down 2% https://seekingalpha.com/news/3517219-cytokinetics-prices-convertible-debt-offering-shares-down-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3517219-cytokinetics-prices-convertible-debt-offering-shares-down-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517218\" data-ts=\"1573224207\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WEN\" target=\"_blank\">WEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517218-wendys-in-100m-accelerated-buyback-pact\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wendy&#39;s in $100M accelerated buyback pact</a></h4><ul><li>Wendy's (<a href='https://seekingalpha.com/symbol/WEN' title='The Wendy&#39;s Company'>WEN</a> <font color='green'>+1.8%</font>) says it entered into a $100M accelerated share buyback agreement with Morgan Stanley.</li><li>The buyback agreement cover 4.05M shares.</li><li><a href=\"https://seekingalpha.com/filing/4692582\" target=\"_blank\">SEC Form 8-K</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3517218\" data-linked=\"Wendy&#39;s in $100M accelerated buyback pact\" data-tweet=\"$WEN - Wendy&#39;s in $100M accelerated buyback pact https://seekingalpha.com/news/3517218-wendys-in-100m-accelerated-buyback-pact?source=tweet\" data-url=\"https://seekingalpha.com/news/3517218-wendys-in-100m-accelerated-buyback-pact\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517215\" data-ts=\"1573223491\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STMP\" target=\"_blank\">STMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517215-stamps-com-boosted-after-raised-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stamps.com boosted after raised outlook</a></h4><ul><li>Roth maintains a Neutral rating on Stamps.com (NASDAQ:<a href='https://seekingalpha.com/symbol/STMP' title='Stamps.com Inc.'>STMP</a>) and raises the target by $5 to $90 after yesterday's <a href=\"https://seekingalpha.com/news/3516918-stamps-com-plus-17_6-percent-beats-fy-outlook-raise\" target=\"_blank\">earnings report</a>.</li><li>The firm says the FY outlook raise was likely due to a USPS reseller extension and a modest UPS rollout.</li><li>On the earnings call, Stamps said its existing USPS reseller agreements were extended through the end of 2019. The company says it understands the USPS will restructure reseller economics next year, and it isn't clear what impact this will have on Stamps.com.</li><li>Stamps.com shares are <font color=\"green\">up 18.7%</font> pre-market to $95.93. The company has a Neutral <a href=\"https://seekingalpha.com/symbol/STMP/ratings/quant-ratings\" target=\"_blank\">Quant rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517215\" data-linked=\"Stamps.com boosted after raised outlook\" data-tweet=\"$STMP - Stamps.com boosted after raised outlook https://seekingalpha.com/news/3517215-stamps-com-boosted-after-raised-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3517215-stamps-com-boosted-after-raised-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:31 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517207\" data-ts=\"1573222912\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WWE\" target=\"_blank\">WWE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517207-wweplus-3_6-on-citi-upgrade-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WWE +3.6% on Citi upgrade to Buy</a></h4><ul>   <li>World Wrestling Entertainment (NYSE:<a href='https://seekingalpha.com/symbol/WWE' title='World Wrestling Entertainment, Inc.'>WWE</a>) is <font color=\"green\">up 3.6%</font> premarket after an upgrade to Buy at Citi, from Neutral.</li>    <li>That's based on an attractive risk-reward assessment from analyst Jason Bazinet.</li>    <li>A price target of $73 implies 34% upside from yesterday's close.</li>    <li>Sell-side analysts are <a href=\"https://seekingalpha.com/symbol/WWE/ratings/sell-side-ratings\" target=\"_blank\">Very Bullish on the stock</a> on average, while <a href=\"https://seekingalpha.com/symbol/WWE/ratings/author-ratings\" target=\"_blank\">Seeking Alpha authors are Neutral</a>. It has a <a href=\"https://seekingalpha.com/symbol/WWE/ratings/quant-ratings\" target=\"_blank\">Quant Rating of Very Bearish</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3517207\" data-linked=\"WWE +3.6% on Citi upgrade to Buy\" data-tweet=\"$WWE - WWE +3.6% on Citi upgrade to Buy https://seekingalpha.com/news/3517207-wweplus-3_6-on-citi-upgrade-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3517207-wweplus-3_6-on-citi-upgrade-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517206\" data-ts=\"1573222721\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517206-dis-gpro-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DIS, GPRO among premarket gainers</a></h4><ul><li>Dermira (NASDAQ:<a href='https://seekingalpha.com/symbol/DERM' title='Dermira, Inc.'>DERM</a>) <font color=\"green\">+29%</font> on apparent reaction to AnaptysBio's <a href=\"https://seekingalpha.com/news/3517203-anaptysbios-pain-dermiras-gain-27-percent-premarket\" target=\"_blank\">etokimab flop</a> in a mid-stage atopic dermatitis study.</li><li>ObsEva SA (NASDAQ:<a href='https://seekingalpha.com/symbol/OBSV' title='ObsEva SA'>OBSV</a>) <font color=\"green\">+21%</font>.</li><li>Sientra (NASDAQ:<a href='https://seekingalpha.com/symbol/SIEN' title='Sientra, Inc.'>SIEN</a>) <font color=\"green\">+16%</font> after <a href=\"https://seekingalpha.com/news/3516653-sientra-eps-beats-0_02-beats-revenue\" target=\"_blank\">Q3 results</a>.</li><li>TrueCar (NASDAQ:<a href='https://seekingalpha.com/symbol/TRUE' title='TrueCar, Inc.'>TRUE</a>) <font color=\"green\">+15%</font> after <a href=\"https://seekingalpha.com/news/3516748-truecar-eps-beats-0_03-beats-revenue\" target=\"_blank\">Q3 results</a>.</li><li>Fastly (NYSE:<a href='https://seekingalpha.com/symbol/FSLY' title='Fastly, Inc.'>FSLY</a>) <font color=\"green\">+15%</font> after <a href=\"https://seekingalpha.com/news/3516666-fastly-eps-beats-0_04-beats-revenue\" target=\"_blank\">Q3 results</a>.</li><li>Iovance Biotherapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/IOVA' title='Iovance Biotherapeutics, Inc.'>IOVA</a>) <font color=\"green\">+14%</font> on <a href=\"https://seekingalpha.com/news/3517120-iovance-12-percent-premarket-positive-lifileucel-data\" target=\"_blank\">positive</a> lifileucel data.</li><li>Zillow Group (NASDAQ:<a href='https://seekingalpha.com/symbol/Z' title='Zillow Group, Inc.'>Z</a>) <font color=\"green\">+11%</font> after <a href=\"https://seekingalpha.com/news/3517120-iovance-12-percent-premarket-positive-lifileucel-data\" target=\"_blank\">Q3 results</a>.</li><li>Ubiquiti (NYSE:<a href='https://seekingalpha.com/symbol/UI' title='Ubiquiti Inc.'>UI</a>) <font color=\"green\">+10%</font> after <a href=\"https://seekingalpha.com/news/3517154-ubiquiti-eps-beats-0_16-beats-revenue\" target=\"_blank\">Q1 results</a>.</li><li>Obalon Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/OBLN' title='Obalon Therapeutics, Inc.'>OBLN</a>) <font color=\"green\">+10%</font> after <a href=\"https://seekingalpha.com/news/3517110-obalon-therapeutics-eps-0_61\" target=\"_blank\">Q3 results</a>.</li><li>Planet Fitness (NYSE:<a href='https://seekingalpha.com/symbol/PLNT' title='Planet Fitness, Inc.'>PLNT</a>) <font color=\"green\">+10%</font> after <a href=\"https://seekingalpha.com/news/3516672-planet-fitness-eps-line-beats-revenue\" target=\"_blank\">Q3 results</a>.</li><li>Party City Holdco (NYSE:<a href='https://seekingalpha.com/symbol/PRTY' title='Party City Holdco Inc.'>PRTY</a>) <font color=\"green\">+10%</font> after <a href=\"https://seekingalpha.com/news/3516222-party-city-eps-misses-0_29-misses-revenue\" target=\"_blank\">Q3 results</a>.</li><li>Zillow Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ZG' title='Zillow Group, Inc.'>ZG</a>) <font color=\"green\">+10%</font> after <a href=\"https://seekingalpha.com/news/3517120-iovance-12-percent-premarket-positive-lifileucel-data\" target=\"_blank\">Q3 results</a>.</li><li>Allena Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ALNA' title='Allena Pharmaceuticals, Inc.'>ALNA</a>) <font color=\"green\">+10%</font>.</li><li>GoPro (NASDAQ:<a href='https://seekingalpha.com/symbol/GPRO' title='GoPro, Inc.'>GPRO</a>) <font color=\"green\">+7%</font> after <a href=\"https://seekingalpha.com/news/3516641-gopro-eps-beats-0_06-beats-revenue\" target=\"_blank\">Q3 results</a>.</li><li>The Walt Disney (NYSE:<a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a>) <font color=\"green\">+6%</font> after <a href=\"https://seekingalpha.com/news/3516651-walt-disney-eps-beats-0_10-beats-revenue\" target=\"_blank\">Q4 results</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517206\" data-linked=\"DIS, GPRO among premarket gainers\" data-tweet=\"$DERM $OBSV $SIEN - DIS, GPRO among premarket gainers https://seekingalpha.com/news/3517206-dis-gpro-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3517206-dis-gpro-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517203\" data-ts=\"1573222325\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DERM\" target=\"_blank\">DERM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517203-anaptysbios-pain-is-dermiras-gain-up-27-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AnaptysBio&#39;s pain is Dermira&#39;s gain, up 27% premarket</a></h4><ul><li>Dermira (NASDAQ:<a href='https://seekingalpha.com/symbol/DERM' title='Dermira, Inc.'>DERM</a>) is up <font color=\"green\">27%</font> premarket on increased volume in apparent reaction to AnaptysBio's <a href=\"https://seekingalpha.com/news/3517192-anaptysbio-lead-drug-flunks-dermatitis-study-shares-74-percent-premarket\" target=\"_blank\">etokimab flop</a> in a mid-stage atopic dermatitis study.</li><li>Investors apparently believe the situation bodes well for the company's <a href=\"https://seekingalpha.com/news/3506961-dermira-29-percent-additional-mid-stage-data-dermatitis-med-lebrikizumab\" target=\"_blank\">lebrikizumab</a>, an IL-13 inhibitor, in <a href=\"https://clinicaltrials.gov/ct2/show/NCT04146363?lead=dermira&amp;phase=2&amp;draw=2&amp;rank=1\" target=\"_blank\">Phase 3</a> development for the same indication.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517203\" data-linked=\"AnaptysBio&#39;s pain is Dermira&#39;s gain, up 27% premarket\" data-tweet=\"$DERM - AnaptysBio&#39;s pain is Dermira&#39;s gain, up 27% premarket https://seekingalpha.com/news/3517203-anaptysbios-pain-is-dermiras-gain-up-27-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3517203-anaptysbios-pain-is-dermiras-gain-up-27-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517201\" data-ts=\"1573222216\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517201-mdr-gps-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MDR, GPS among premarket losers</a></h4><ul><li>AnaptysBio (NASDAQ:<a href='https://seekingalpha.com/symbol/ANAB' title='AnaptysBio, Inc.'>ANAB</a>) <font color=\"red\">-73%</font> after <a href=\"https://seekingalpha.com/news/3517170-anaptysbio-eps-line\" target=\"_blank\">Q3 results</a> and lead <a href=\"https://seekingalpha.com/news/3517192-anaptysbio-lead-drug-flunks-dermatitis-study-shares-74-percent-premarket\" target=\"_blank\">drug flunks</a> dermatitis study.</li><li>Therapix Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/TRPX' title='Therapix Biosciences Ltd.'>TRPX</a>) <font color=\"red\">-40%</font> on mutual decision with Destiny Biosciences Global to <a href=\"https://seekingalpha.com/pr/17692471-therapix-biosciences-destiny-biosciences-global-corp-mutually-decide-discontinue-negotiations\" target=\"_blank\">discontinue negotiations</a> on the previously announced proposed merger.</li><li>Red Lion Hotels (NYSE:<a href='https://seekingalpha.com/symbol/RLH' title='Red Lion Hotels Corporation'>RLH</a>) <font color=\"red\">-34%</font> after <a href=\"https://seekingalpha.com/news/3517102-red-lion-hotels-eps-misses-0_26-misses-revenue\" target=\"_blank\">Q3 results</a>.</li><li>Medifast (NYSE:<a href='https://seekingalpha.com/symbol/MED' title='Medifast, Inc.'>MED</a>) <font color=\"red\">-32%</font> after <a href=\"https://seekingalpha.com/news/3516740-medifast-eps-misses-0_01-misses-revenue\" target=\"_blank\">Q3 results</a>.</li><li>Teradata (NYSE:<a href='https://seekingalpha.com/symbol/TDC' title='Teradata Corporation'>TDC</a>) <font color=\"red\">-25%</font> after <a href=\"https://seekingalpha.com/news/3516704-teradata-eps-misses-0_08-misses-revenue\" target=\"_blank\">Q3 results</a>.</li><li>Green Dot (NYSE:<a href='https://seekingalpha.com/symbol/GDOT' title='Green Dot Corporation'>GDOT</a>) <font color=\"red\">-18%</font> after <a href=\"https://seekingalpha.com/news/3516732-green-dot-eps-beats-0_18-beats-revenue\" target=\"_blank\">Q3 results</a>.</li><li>McDermott International (NYSE:<a href='https://seekingalpha.com/symbol/MDR' title='McDermott International, Inc.'>MDR</a>) <font color=\"red\">-14%</font>.</li><li>Affimed N.V. (NASDAQ:<a href='https://seekingalpha.com/symbol/AFMD' title='Affimed N.V.'>AFMD</a>) <font color=\"red\">-11%</font> after <a href=\"https://seekingalpha.com/news/3517073-affimed-8-percent-premarket-pricing-stock-offering\" target=\"_blank\">pricing stock offering</a>.</li><li>Bionano Genomics (NASDAQ:<a href='https://seekingalpha.com/symbol/BNGO' title='Bionano Genomics, Inc.'>BNGO</a>) <font color=\"red\">-11%</font> after <a href=\"https://seekingalpha.com/news/3516883-bionano-genomics-beats-revenue\" target=\"_blank\">Q3 results</a>.</li><li>Turtle Beach (NASDAQ:<a href='https://seekingalpha.com/symbol/HEAR' title='Turtle Beach Corporation'>HEAR</a>) <font color=\"red\">-9%</font> after <a href=\"https://seekingalpha.com/news/3516682-turtle-beach-eps-beats-0_09-beats-revenue\" target=\"_blank\">Q3 results</a>.</li><li>The Gap (NYSE:<a href='https://seekingalpha.com/symbol/GPS' title='The Gap, Inc.'>GPS</a>) <font color=\"red\">-8%</font> after <a href=\"https://seekingalpha.com/news/3516738-gap-minus-7-percent-slashing-guidance-ceo-exit\" target=\"_blank\">slashing guidance</a> and CEO exit.</li><li>Agios Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AGIO' title='Agios Pharmaceuticals, Inc.'>AGIO</a>) <font color=\"red\">-6% </font>on <a href=\"https://seekingalpha.com/news/3517042-agios-prices-256m-equity-offering-shares-3_8-percent-premarket\" target=\"_blank\">pricing</a> of $256M equity offering.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517201\" data-linked=\"MDR, GPS among premarket losers\" data-tweet=\"$ANAB $TRPX $RLH - MDR, GPS among premarket losers https://seekingalpha.com/news/3517201-mdr-gps-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3517201-mdr-gps-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517199\" data-ts=\"1573222008\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPS\" target=\"_blank\">GPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517199-gapminus-10-investors-puzzle-over-new-direction\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gap -10% as investors puzzle over new direction</a></h4><ul><li>While investors are reacting to the shock exit of Gap (NYSE:<a href='https://seekingalpha.com/symbol/GPS' title='The Gap, Inc.'>GPS</a>) CEO Art Peck, analysts are puzzling over what the development means for the planned spinoff of Old Navy.</li><li>Citi thinks the Old Navy separation is likely to be pulled from the table when the Gap board meets next week.</li><li>Evercore ISI is of a like mind. \"We have to think this new development will make the original timeline of the planned Old Navy separation extremely difficult,\" writes analyst Westcott Rochett.</li><li>More of the same from Morningstar. \"We think the Old Navy spin should be scrapped ... it makes little sense to spin Old Navy until, at least, its sales have stabilized,\" says analyst David Swartz. \"We see little future for a Gap without Old Navy ... it is difficult to see how Gap can attract a top-flight CEO to fix the company if it is going to be stripped of Old Navy, its best asset,\" he adds.</li><li>Shares of Gap are <font color=\"red\">down 9.66%</font> premarket to $16.36.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3516738-gap-minus-7-percent-slashing-guidance-ceo-exit\" target=\"_blank\">Gap -7% after slashing guidance and CEO exit</a> (Nov. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3517199\" data-linked=\"Gap -10% as investors puzzle over new direction\" data-tweet=\"$GPS - Gap -10% as investors puzzle over new direction https://seekingalpha.com/news/3517199-gapminus-10-investors-puzzle-over-new-direction?source=tweet\" data-url=\"https://seekingalpha.com/news/3517199-gapminus-10-investors-puzzle-over-new-direction\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517194\" data-ts=\"1573221402\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HEAR\" target=\"_blank\">HEAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517194-bull-trims-turtle-beach-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bull trims Turtle Beach after earnings</a></h4><ul><li>Wedbush (Outperform) lowers its Turtle Beach (NASDAQ:<a href='https://seekingalpha.com/symbol/HEAR' title='Turtle Beach Corporation'>HEAR</a>) target by a dollar to $14 after yesterday's <a href=\"https://seekingalpha.com/news/3516828-turtle-beach-minus-16-percent-downside-eps-outlook\" target=\"_blank\">Q3 beats</a> and downside FY EPS outlook.</li><li>The firm says the results were \"decent\" but isn't yet convinced the console refresh will drive growth.</li><li>Wedbush sees \"relatively slow consolidated revenue growth for the next few years.\"</li><li>HEAR shares are <font color=\"red\">down 8.3%</font> pre-market to $9.17. The company has a Very Bullish average <a href=\"https://seekingalpha.com/symbol/HEAR/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating. </a></li></ul><div class=\"tiny-share-widget\" data-id=\"3517194\" data-linked=\"Bull trims Turtle Beach after earnings\" data-tweet=\"$HEAR - Bull trims Turtle Beach after earnings https://seekingalpha.com/news/3517194-bull-trims-turtle-beach-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3517194-bull-trims-turtle-beach-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517192\" data-ts=\"1573221292\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANAB\" target=\"_blank\">ANAB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517192-anaptysbio-lead-drug-flunks-dermatitis-study-shares-down-74-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AnaptysBio lead drug flunks dermatitis study; shares down 74% premarket</a></h4><ul><li>Thinly traded AnaptysBio (NASDAQ:<a href='https://seekingalpha.com/symbol/ANAB' title='AnaptysBio, Inc.'>ANAB</a>) craters <font color=\"red\">74%</font> premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/17692962-anaptysbio-reports-etokimab-atlas-phase-2b-clinical-trial-moderate-severe-atopic-dermatitis\" target=\"_blank\">announcement </a>that lead candidate etokimab failed to achieve the primary endpoint in a Phase 2b clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03533751?cond=Atopic+Dermatitis&amp;lead=anaptysbio&amp;phase=1&amp;draw=2&amp;rank=1\" target=\"_blank\">ATLAS</a>, in patients with moderate-to-severe atopic dermatitis.</li><li>Specifically, etokimab, an IL-33 inhibitor, failed to sufficiently separate from placebo as measured by the percent change in a scale called EASI at week 16. Additional data will be released next quarter.</li><li>In light of the disappointing outcome, the company has decided to postpone the launch of its Phase 2b study evaluating etokimab in eosinophilic asthma.</li><li>The ongoing Phase 2 <a href=\"https://clinicaltrials.gov/ct2/show/NCT03614923?lead=anaptysbio&amp;phase=1&amp;draw=2&amp;rank=3\" target=\"_blank\">ECLIPSE </a>trial in patients with chronic rhinosinusitis with nasal polyps will continue. Topline results should also be available next quarter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517192\" data-linked=\"AnaptysBio lead drug flunks dermatitis study; shares down 74% premarket\" data-tweet=\"$ANAB - AnaptysBio lead drug flunks dermatitis study; shares down 74% premarket https://seekingalpha.com/news/3517192-anaptysbio-lead-drug-flunks-dermatitis-study-shares-down-74-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3517192-anaptysbio-lead-drug-flunks-dermatitis-study-shares-down-74-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517188\" data-ts=\"1573221027\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UI\" target=\"_blank\">UI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517188-ubiquitiplus-9-after-beats-200m-buyback\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ubiquiti +9% after beats, $200M buyback</a></h4><ul><li>Ubiquiti (NYSE:<a href='https://seekingalpha.com/symbol/UI' title='Ubiquiti Inc.'>UI</a>) <font color=\"green\">+9.3%</font> reports <a href=\"https://seekingalpha.com/news/3517154-ubiquiti-eps-beats-0_16-beats-revenue\" target=\"_blank\">Q1 beats</a> with 14% Y/Y revenue growth and announces adding $200M under a new share repurchase program, which expires at the end of 2021.</li><li>Service Provider Technology revenue totaled $115.9M compared to the $105M in last year's quarter. Enterprise Technology revenue was $207.4M versus $177.9M.</li><li>Gross profit rose from 46.5% to 46.8%.</li><li><a href=\"https://seekingalpha.com/pr/17692922-ubiquiti-inc-reports-first-quarter-fiscal-2020-financial-results\" target=\"_blank\">Press release</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517188\" data-linked=\"Ubiquiti +9% after beats, $200M buyback\" data-tweet=\"$UI - Ubiquiti +9% after beats, $200M buyback https://seekingalpha.com/news/3517188-ubiquitiplus-9-after-beats-200m-buyback?source=tweet\" data-url=\"https://seekingalpha.com/news/3517188-ubiquitiplus-9-after-beats-200m-buyback\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517186\" data-ts=\"1573220925\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REV\" target=\"_blank\">REV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517186-negative-results-in-north-america-business-for-revlon-in-q3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Negative results in the North America business for Revlon in Q3</a></h4><ul><li>Revlon (NYSE:<a href='https://seekingalpha.com/symbol/REV' title='Revlon, Inc.'>REV</a>) reports net sales declined 7.1% on a constant currency basis in <a href=\"https://seekingalpha.com/pr/17692868-revlon-reports-third-quarter-2019-results\" sasource=\"qp_sum_news_8\" target=\"_blank\">Q3</a>, driven primarily by net sales declines in the Portfolio and Revlon segments.</li><li>Revlon segment net sales dropped 12.9% to $217.3M, driven primarily by lower net sales of Revlon color cosmetics due to retailer inventory management and overall category declines, combined with increased promotionality, primarily in North America.</li><li>Elizabeth Arden net sales up 0.9% to $123.2M, driven by higher net sales of Elizabeth Arden skin care products, including Ceramide and Prevage, primarily internationally.</li><li>Portfolio Segment net sales squeezed 14.6% to $118.2M, driven primarily by the segment's lower net sales of Almay color cosmetics, CND nail products and Pure Ice nail polishes.</li><li>Fragrances Segment net sales slipped 5% to $138.1M, driven primarily by the segment's lower net sales of Juicy Couture and Britney Spears branded fragrances due to timing of innovation.</li><li>Total North America sales decreased 14.6% to $299.5M and International sales -2.4% to $297.3M.</li><li>Adjusted gross margin rate slipped 50 bps to 55.1%.</li><li>Adjusted EBITDA fell 5.5% to $68.4M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3517119-revlon-eps-beats-0_12-misses-revenue\" target=\"_blank\">Revlon EPS beats by $0.12, misses on revenue</a> (Nov. 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3517186\" data-linked=\"Negative results in the North America business for Revlon in Q3\" data-tweet=\"$REV - Negative results in the North America business for Revlon in Q3 https://seekingalpha.com/news/3517186-negative-results-in-north-america-business-for-revlon-in-q3?source=tweet\" data-url=\"https://seekingalpha.com/news/3517186-negative-results-in-north-america-business-for-revlon-in-q3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517175\" data-ts=\"1573219696\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FSLY\" target=\"_blank\">FSLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517175-fastlyplus-18-after-beats-fy-revenue-raise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fastly +18% after beats, FY revenue raise</a></h4><ul><li>Fastly (NYSE:<a href='https://seekingalpha.com/symbol/FSLY' title='Fastly, Inc.'>FSLY</a>) <font color=\"green\">gains 17.7%</font> before the bell after yesterday's <a href=\"https://seekingalpha.com/news/3516666-fastly-eps-beats-0_04-beats-revenue\" target=\"_blank\">Q3 beats</a> and guidance increase.</li><li>The inline Q4 guidance sees $52.5-56.5M in revenue and a loss per share of $0.13 to $0.10.</li><li>The upside FY19 outlook has revenue of $194-198M (consensus: $192.88M; was: $191-195M) and loss per share of $0.54 to $0.51 (consensus: $0.58 loss).</li><li><a href=\"https://seekingalpha.com/pr/17692102-fastly-announces-third-quarter-2019-financial-results\" target=\"_blank\">Press release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3517175\" data-linked=\"Fastly +18% after beats, FY revenue raise\" data-tweet=\"$FSLY - Fastly +18% after beats, FY revenue raise https://seekingalpha.com/news/3517175-fastlyplus-18-after-beats-fy-revenue-raise?source=tweet\" data-url=\"https://seekingalpha.com/news/3517175-fastlyplus-18-after-beats-fy-revenue-raise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517157\" data-ts=\"1573218524\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLM\" target=\"_blank\">PLM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517157-polymet-mining-eps-beats-0_01\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PolyMet Mining EPS beats by $0.01</a></h4><ul><li>PolyMet Mining (NYSEMKT:<a href='https://seekingalpha.com/symbol/PLM' title='PolyMet Mining Corp.'>PLM</a>): Q3 GAAP EPS of $0.00 <font color=\"green\">beats by $0.01</font>.</li><li>Cash of $15M.</li><li>Shares <font color=\"green\">+4.73%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17692901-polymet-reports-results-period-ended-september-30-2019\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3517157\" data-linked=\"PolyMet Mining EPS beats by $0.01\" data-tweet=\"$PLM - PolyMet Mining EPS beats by $0.01 https://seekingalpha.com/news/3517157-polymet-mining-eps-beats-0_01?source=tweet\" data-url=\"https://seekingalpha.com/news/3517157-polymet-mining-eps-beats-0_01\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517156\" data-ts=\"1573218502\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517156-now-sail-gain-on-new-sector-bull\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NOW, SAIL gain on new sector bull</a></h4><ul><li>Piper Jaffray assumes coverage on a slate of infrastructure security companies with an Overweight rating, saying the names could \"benefit from a multi-year tailwind driven by new digital enterprise mandates and continued cloud growth.\"</li><li>The initiated stocks have \"strong near-term opportunities and longer-term prospects.\"</li><li>New Overweight names with price targets: Fortinet (NASDAQ:<a href='https://seekingalpha.com/symbol/FTNT' title='Fortinet, Inc.'>FTNT</a>) <font color=\"green\">+0.7%</font>, $116; ServiceNow (NYSE:<a href='https://seekingalpha.com/symbol/NOW' title='ServiceNow, Inc.'>NOW</a>) <font color=\"green\">+1.8%</font>, $305; Okta (NASDAQ:<a href='https://seekingalpha.com/symbol/OKTA' title='Okta, Inc.'>OKTA</a>) <font color=\"green\">+0.4%</font>, $135; Proofpoint (NASDAQ:<a href='https://seekingalpha.com/symbol/PFPT' title='Proofpoint, Inc.'>PFPT</a>) <font color=\"green\">+0.3%</font>, $155; SailPoint (NYSE:<a href='https://seekingalpha.com/symbol/SAIL' title='SailPoint Technologies Holdings, Inc.'>SAIL</a>) <font color=\"green\">+2.6%</font>, $30; Splunk (NASDAQ:<a href='https://seekingalpha.com/symbol/SPLK' title='Splunk Inc.'>SPLK</a>) <font color=\"green\">+0.2%</font>, $160.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517156\" data-linked=\"NOW, SAIL gain on new sector bull\" data-tweet=\"$FTNT $NOW $OKTA - NOW, SAIL gain on new sector bull https://seekingalpha.com/news/3517156-now-sail-gain-on-new-sector-bull?source=tweet\" data-url=\"https://seekingalpha.com/news/3517156-now-sail-gain-on-new-sector-bull\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517154\" data-ts=\"1573218424\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UI\" target=\"_blank\">UI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517154-ubiquiti-eps-beats-0_16-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ubiquiti EPS beats by $0.16, beats on revenue</a></h4><ul><li>Ubiquiti (NYSE:<a href='https://seekingalpha.com/symbol/UI' title='Ubiquiti Inc.'>UI</a>): Q1 Non-GAAP EPS of $1.44 <font color=\"green\">beats by $0.16</font>; GAAP EPS of $1.43 <font color=\"green\">beats by $0.14</font>.</li><li>Revenue of $323.3M (+14.3% Y/Y) <font color=\"green\">beats by $15.35M</font>.</li><li>Shares <font color=\"green\">+11.55%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17692922-ubiquiti-inc-reports-first-quarter-fiscal-2020-financial-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3517154\" data-linked=\"Ubiquiti EPS beats by $0.16, beats on revenue\" data-tweet=\"$UI - Ubiquiti EPS beats by $0.16, beats on revenue https://seekingalpha.com/news/3517154-ubiquiti-eps-beats-0_16-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3517154-ubiquiti-eps-beats-0_16-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517149\" data-ts=\"1573218185\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANAB\" target=\"_blank\">ANAB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517149-anaptysbio-shares-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AnaptysBio shares halted pending news</a></h4><ul><li>Nasdaq has suspended trading in AnaptysBio (NASDAQ:<a href='https://seekingalpha.com/symbol/ANAB' title='AnaptysBio, Inc.'>ANAB</a>) pending the release of news.</li></ul><div class=\"tiny-share-widget\" data-id=\"3517149\" data-linked=\"AnaptysBio shares halted pending news\" data-tweet=\"$ANAB - AnaptysBio shares halted pending news https://seekingalpha.com/news/3517149-anaptysbio-shares-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3517149-anaptysbio-shares-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517148\" data-ts=\"1573218174\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SELB\" target=\"_blank\">SELB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517148-selecta-biosciences-eps-beats-0_07\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Selecta Biosciences EPS beats by $0.07</a></h4><ul><li>Selecta Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SELB' title='Selecta Biosciences, Inc.'>SELB</a>): Q3 GAAP EPS of -$0.26 <font color=\"green\">beats by $0.07</font>.</li><li>Cash, equivalents and restricted cash of $34.51M.</li><li>Shares <font color=\"green\">+3.9%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17692928-selecta-biosciences-reports-third-quarter-2019-financial-results-provides-corporate-update\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3517148\" data-linked=\"Selecta Biosciences EPS beats by $0.07\" data-tweet=\"$SELB - Selecta Biosciences EPS beats by $0.07 https://seekingalpha.com/news/3517148-selecta-biosciences-eps-beats-0_07?source=tweet\" data-url=\"https://seekingalpha.com/news/3517148-selecta-biosciences-eps-beats-0_07\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517143\" data-ts=\"1573218068\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GH\" target=\"_blank\">GH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517143-guardant-health-up-11-premarket-on-q3-beat-guidance-boost\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Guardant Health up 11% premarket on Q3 beat, guidance boost</a></h4><ul><li>Guardant Health (NASDAQ:<a href='https://seekingalpha.com/symbol/GH' title='Guardant Health, Inc.'>GH</a>) is up <font color=\"green\">11%</font> premarket on light volume following its <a href=\"https://seekingalpha.com/pr/17692091-guardant-health-reports-third-quarter-2019-financial-results-raises-2019-revenue-guidance\" target=\"_blank\">Q3 results</a> released after the close yesterday. Highlights:</li><li>Revenue: $60.8M (+180%).</li><li>Net loss: ($12.8M) (+48%); loss/share: ($0.14) (+93%).</li><li>13,259 (+89%) tests reported to clinical customers, 5,280 (+111%) to biopharma customers.</li><li><strong>2019 guidance</strong>: Revenue: $202M - 207M from $180M - 190M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3516662-guardant-health-eps-beats-0_23-beats-revenue\" target=\"_blank\">Guardant Health EPS beats by $0.23, beats on revenue</a> (Nov. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3517143\" data-linked=\"Guardant Health up 11% premarket on Q3 beat, guidance boost\" data-tweet=\"$GH - Guardant Health up 11% premarket on Q3 beat, guidance boost https://seekingalpha.com/news/3517143-guardant-health-up-11-premarket-on-q3-beat-guidance-boost?source=tweet\" data-url=\"https://seekingalpha.com/news/3517143-guardant-health-up-11-premarket-on-q3-beat-guidance-boost\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3517141\" data-ts=\"1573217975\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLNT\" target=\"_blank\">PLNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3517141-planet-fitnessplus-10-australia-enters-mix\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Planet Fitness +10% as Australia enters the mix</a></h4><ul><li>Planet Fitness (NYSE:<a href='https://seekingalpha.com/symbol/PLNT' title='Planet Fitness, Inc.'>PLNT</a>) jumps in early trading after topping sales estimates and issuing solid guidance.</li><li>The company also detailed its jump into Australia during the earnings conference call (<a href=\"https://seekingalpha.com/article/4304163-planet-fitness-inc-plnt-ceo-chris-rondeau-q3-2019-results-earnings-call-transcript\" target=\"_blank\">transcript)</a>, which could be accounting for some of the investor enthusiasm.</li><li>\"Our entry into the Australian market is being led by a partnership between two existing U.S. franchise groups who joint forces with a local Australian fitness operator who own the trademark of the Planet Fitness in his name Australia and operated several locations in New South Wales.\"</li><li>PLNT <font color=\"green\">+9.55%</font> premarket to $68.70.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3516763-planet-fitness-plus-3-percent-strong-comparable-sales\" target=\"_blank\">Planet Fitness +3% after strong comparable sales</a> (Nov. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3517141\" data-linked=\"Planet Fitness +10% as Australia enters the mix\" data-tweet=\"$PLNT - Planet Fitness +10% as Australia enters the mix https://seekingalpha.com/news/3517141-planet-fitnessplus-10-australia-enters-mix?source=tweet\" data-url=\"https://seekingalpha.com/news/3517141-planet-fitnessplus-10-australia-enters-mix\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}